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ABSTRACT 
In todays’ global economy, having a lean operation is no longer considered a 
competitive edge;  rather has become the new necessity and norm [15]. The new source of this 
competitive edge is innovation [15].  What sets an organization apart from its competitors is 
the ability to develop products that constantly meet customers’ demands. An organization 
must have a New Product Development Process (NPDP) that enhances, expedites and fosters 
development of innovative products on consistent basis in order to tie innovation to market 
success. Many organizations have a difficult time determining whether or not the NPDP they 
are using is adequate because there are no standard methods or processes that organization 
can use to assess their NPDP [16].  In order to assist a specific medical device organization to 
assess its NPDP, a partnership with Performance Measure Group (PMG) was established. PMG 
is a leader in benchmarking and performance measurement.  This thesis gives insight into the 
various new product development and benchmarking processes that are in practice today.  It 
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also explores the challenges and benefits associated with conducting benchmarking. Finally, 
this thesis reveals some of the challenges that this particular medical device company confronts 
with their NPDP. 
 
  
 Page 5 
 
ACKNOWLEDGEMENTS: FAMILY AND FREINDS 
Thank you to my father and mother, Moussa and Parvaneh, who have made many 
sacrifices in their lives so I can have better opportunities in my life.  I would also like to thank 
my brother and sister, Sami and Sahar, who have always been supportive of what I do. 
Thank you both Michal Berdugo and Cynthia Yee for editing this paper.  You are both 
wonderful friends and I am very lucky to have you.  I would like to thank you both for all the 
time you spent editing this paper. 
DEDICATION 
This thesis is dedicated to the memory of my grandfathers and grandmothers: Sasson 
Zelkha, Victoria Zelkha, Abraham and Anbar Navian. 
  
 Page 6 
 
ACKNOWLEDGEMENTS: MIT COMMUNITY 
Professor Daniel Whitney is a great mentor and teacher. Throughout this thesis he has 
guided me to think differently and explore new ideas.  I have learned many things from 
Professor Whitney, but above all, he has thought me the art of asking the right questions. I am 
forever grateful to Professor Whitney and I am very fortunate to have him as my advisor and 
mentor.  
This thesis would not have been possible without Professor Seering’s help. Professor 
Seering was the thesis advisor to Brad Householder twenty years ago at MIT and made the 
introduction between Mr. Householder, PMG and myself. Thank you to Professor Seering for all 
of your help and mentoring.  
I would like to thank other members of Massachusetts Institute of Technology who have 
always supported and helped the SDM students achieve success.  I have never worked with a 
finer group of people who have tirelessly committed themselves to making SDM a better place. 
Thank you to Pat Hale, Chris Bates, David Erickson, Helen Trimble and Bill Foley. 
  
 Page 7 
 
ACKNOWLEDGEMENTS: PwC and PMG  
I would like to give a special thanks to member of PMG without whom this thesis would 
have been possible. PMG is a great organization that has pushed the boundaries of 
benchmarking and performance measurement throughout the years.  I have been very 
fortunate to have had an opportunity to work with the PMG group and to learn from the best 
professionals in the industry. I would like to especially thank the following members of the PMG 
organization who allowed me to utilize their knowledge and their processes to conduct this 
benchmarking study. Thank you to Brad Householder, Glenn R Heywood, Steven Coates, Sharad 
Narayan and Douglas Billings.  
  
 Page 8 
 
TABLE OF CONTENTS 
ABSTRACT ............................................................................................................................. 3 
ACKNOWLEDGEMENTS: FAMILY AND FREINDS....................................................................... 5 
DEDICATION .......................................................................................................................... 5 
ACKNOWLEDGEMENTS: MIT COMMUNITY............................................................................. 6 
ACKNOWLEDGEMENTS: PwC and PMG .................................................................................. 7 
LIST OF FIGURES .................................................................................................................. 10 
LIST OF ACRONYMS ............................................................................................................. 12 
1 INTRODUCTION AND MOTIVATION .............................................................................. 14 
1.1 INTRODUCTION TO MEDICAL DEVICE INDUSTRY ............................................................................ 14 
1.1.1 Medical Device Industry Market Overview ........................................................................... 15 
1.1.2 Medical Devices-In Vitro Diagnostic ...................................................................................... 17 
1.1.3 Regulation of Medical Device Development ......................................................................... 21 
1.2 OBJECTIVES ..................................................................................................................................... 22 
1.2.1 Methodology ......................................................................................................................... 24 
2 LITERATURE REVIEW .................................................................................................... 26 
2.1 INTRODUCTION ............................................................................................................................... 26 
2.1.1 What Is New Product Development Process ......................................................................... 26 
2.1.2 Phase-Gate/Waterfall NPDP .................................................................................................. 31 
2.1.3 Iterative NPDP Process .......................................................................................................... 37 
2.1.4 NPDP Conclusion ................................................................................................................... 41 
2.1.5 What Is Benchmarking? ......................................................................................................... 41 
3 BENCHMARKING METHODOLOGY AND RESULTS .......................................................... 49 
3.1 INTRODUCTION ............................................................................................................................... 49 
3.1.1 PMG Methodology ................................................................................................................ 51 
3.1.2 Basic Principles behind PMG Methodology ........................................................................... 51 
3.1.3 Use Context and Challenges .................................................................................................. 55 
3.1.4 Who was Benchmarked ......................................................................................................... 59 
3.2 Method of Collecting Data for PMG Benchmarking ........................................................................ 60 
 Page 9 
 
3.3 RESULTS ........................................................................................................................................... 61 
3.3.1 Result from PMG Case Study Company A ............................................................................. 61 
3.3.2 DSM Analysis of the NPDP ..................................................................................................... 69 
3.3.3 Interviews: ............................................................................................................................. 76 
4 CONCLUSIONS AND RECOMMENDATIONS .................................................................... 79 
4.1 PERSONAL INSIGHT ......................................................................................................................... 79 
4.1.1 INTRODUCTION ..................................................................................................................... 79 
4.1.2 CHALLENGES .......................................................................................................................... 79 
4.1.3 LESSONS LEARNED FROM BENCHMARKING .......................................................................... 80 
4.2 ADVANTAGES AND DISADVANTAGES OF PMG BENCHMARKING ................................................... 83 
4.2.1 Advantages ............................................................................................................................ 83 
4.2.2 Limitation ............................................................................................................................... 84 
4.3 CONCLUSION OF ORGANIZATION BENCHMARKING AND RECOMMENDATION ............................. 85 
5 BIBLIOGRAPHY ............................................................................................................. 88 
 
  
 Page 10 
 
LIST OF FIGURES 
Figure 1: Al-Zahrawia Illustration of Various Medical Devices of 9TH & 10TH Century [10] ...... 14 
Figure 2: Medical Device Market-Total Revenue: 2007 to 2011 [5] ....................................... 15 
Figure 3: Total Revenue Based on Major Markets:2007 to 2011 [5] ...................................... 15 
Figure 4: Medical Device Market: Top 30 Companies Ranked Based on Revenue [4] ............. 16 
Figure 5: CAGR and Total Revenue Each Medical Device Category [5] ................................... 16 
Figure 6: IVD Total Revenue Break Down [4] ........................................................................ 18 
Figure 7: Company Market Share as Function of % Revenue [4] ............................................ 18 
Table 1: Predicted Revenue as Function of IVD Type [4] ....................................................... 19 
Figure 8: Market Driver, Challenges and Trends [4] .............................................................. 20 
Figure 9: Application of Design Controls to Waterfall Design Process [13] ............................. 22 
Figure 10: R&D Spending vs. Sales Growth. [6] ..................................................................... 29 
Figure 11: Managements Decision Points [14] ...................................................................... 30 
Figure 12: Generic 6 Phase NPDP- The Non-Iterative Version ............................................... 32 
Figure 13: Iterative Phase-Gate/Waterfall ............................................................................ 33 
Figure 14: Phase-Gate Go or No-Go Decision Points [12] ...................................................... 34 
Figure 15: Management Contribution and Impact [12] ......................................................... 35 
Figure 16: The V-Model ....................................................................................................... 35 
Figure 17: Various Versions of Phase-Gate Processes [14] .................................................... 36 
Figure 18: Typical Modified Phase-Gate ............................................................................... 37 
Figure 19: Spiral NPDP [7] .................................................................................................... 38 
Figure 20: Design-To-Schedule or Budget [8] ........................................................................ 39 
Figure 21: NPDP Strengths and Weaknesses [8] ................................................................... 40 
Table 2: Lists of Benchmarking Definitions [53, 58, 61] ......................................................... 42 
Figure 22: Deming Four Stages Applied to Benchmarking [11] .............................................. 46 
Figure 23: A Comprehensive RDEI Calculation [9] ................................................................. 50 
Figure 24: PMG Experienced Working Across the Healthcare Value Chain [3] ....................... 51 
Figure 25: PMG Approach to Benchmarking ......................................................................... 52 
 Page 11 
 
Figure 26: Examples of KPIs Measured  [3] ........................................................................... 53 
Figure 27: The Qualitative Section Focuses Process Maturity  [3] .......................................... 54 
Figure 28: Organization Structure ........................................................................................ 56 
Figure 30: Competitive Strategies [3] ................................................................................... 62 
Figure 31: Organization A Product Development Practices  [3] ............................................. 62 
Figure 32: Financial Performance Comparison  [3] ................................................................ 63 
Figure 33: R&D Breakdown Spending for Average and 'A’ Organization [3] ........................... 63 
Figure 34: Impact of New Product on Total Revenue [3] ....................................................... 64 
Figure 35: Product Development and Break-Even Time. [3] .................................................. 64 
Figure 36: Innovation and Strategy, Leverage and Quality result [3] ..................................... 65 
Figure 37: % PD Staff Activities Breakdown [3] ..................................................................... 65 
Figure 38: Number of Management Levels in R&D [3] .......................................................... 66 
Figure 39: Speed, Cost Management, Quality and Productivity [3] ........................................ 66 
Figure 40: Hardware and Software Reuse for Platforms Development [3] ............................. 67 
Figure 42: Resource, Innovation, Technology & Product Lifecycle Management  [3] ............. 68 
Figure 43: PD specific and Overall Qualitative Results  [3] .................................................... 69 
Figure 44: Example of a Process Mapped into a DSM model [1] ............................................ 70 
Figure 45: An Example of DSM Analysis [2] .......................................................................... 71 
Figure 46: Example of DSM by Donald V. Steward ................................................................ 71 
Figure 47: DSM model of the organization NPDP .................................................................. 72 
Figure 48: Partitioned DSM .................................................................................................. 73 
Figure 49: Concept Phase ..................................................................................................... 74 
Figure 50: Feasibility Phase .................................................................................................. 74 
Figure 51: Coupled Activities ................................................................................................ 75 
Figure 52: Prototype Phase .................................................................................................. 75 
Figure 53: Pre-Manufacturing and Manufacturing Phase ...................................................... 76 
 
  
 Page 12 
 
LIST OF ACRONYMS 
Acronym Meaning 
BIC Best In Class 
BOM Bill Of Material 
CLIA 88 Clinical Laboratory Improvement Amendments of 1988 
CM Contract Manufacturer 
COGS Cost Of Goods Sold 
E.U European Union 
EBIT Earnings Before Interest and Taxes 
ECO Engineering Change Order 
FDA Food and Drug Administration (U.S) 
FEL Front-End Loading 
IVD In-Vitro Diagnostics 
KPIs Key Performance Indicators  
KPIs Key Performance Indicators 
KPLs Key Performance Levers 
ND No Data 
NPDP New Product Development Process 
NR No Response 
ODM Original Design Manufacturer 
PAC Product Approval Committee 
PACE Product And Cycle-time Excellence 
PD Product Development 
PDP Product Development Process 
PIB Product Innovation Benchmark 
PLC Product Life-Cycle 
PMG Performance Measurement Group 
POC Point Of Care 
PPP Pre-Project Planning  
PRTM Pittiglio, Rabin, Todd & McGrath 
PwC PricewaterhouseCoopers  
R&D D1 R&D Division One  
R&D D2 R&D Division Two 
RDEI R&D Effectiveness Index 
 Page 13 
 
SG&A Selling General & Administrative Expense 
SMBG Self-Monitoring of Blood Glucose 
TDT Technology Development Time 
TTM Time To Market 
U.S United States 
WIC Worst In Class 
FFE Fuzzy Front End 
WWII World War II 
NASA National Aeronautics and Space Administration  
PRP Phased Review Process 
DCG Design Control Guidance   
510 (K) Premarket Notification 
DSM Design Structure Matrix 
 
 
  
 Page 14 
 
1 INTRODUCTION AND MOTIVATION 
1.1 INTRODUCTION TO MEDICAL DEVICE INDUSTRY  
The United States Food and Drug Administration (FDA) is the regulatory body that 
defines and regulates the medical device industry in the United States.  Other nations, such as 
the members of the European Union (EU), Japan and China have their own regulatory bodies. 
Throughout this paper, medical devices are defined according to the formal FDA definition: “an 
instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other 
similar or related article, including a component part, or accessory which is intended for use in 
the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention 
of disease, in man or other animals” [13]. The FDA definition of medical devices is broad and 
covers everything from a tongue depressor to pacemakers to a variety of medical imaging 
devices. 
Medical devices have been used by humans 
for centuries. Medical devices such as tweezers and 
ear scoops dating back to 3000 B.C have been found 
in Egypt. Human remains from the Roman and 
Greek eras have been recovered with drilled holes 
in their skulls suggesting that some kinds of 
surgeries were performed using various tools [17]. 
Al-Zahrawia, a physician who lived in the In the 10th 
century, published a book titled Kitab al-Tasrif in 
which he describes various medical devices from his 
time used to perform medical surgeries shown in 
XXX [10].  While some of the medical devices from this time are still in use, the highly 
specialized medical device industry in the United States of today dates back to the early 
Nineteenth century. Prior to the FDA regulation of the medical device industry, medicine was 
decentralized and consisted of general practitioners [18].  Today the medical device industry is 
Figure 1: Al-Zahrawia Illustration of Various 
Medical Devices of 9TH & 10TH Century [10]  
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a result of the shift from the use of subjective evidence provided by the patient to objective 
evidence obtained by mechanical and chemical technology devices [18].  This, coupled with a 
demand for better care by the patients, and advancement in physics and chemistry, fueled the 
formation of specialized medical device industry [18].   
1.1.1 Medical Device Industry Market Overview 
The medical device industry is a 
major part of today’s global economy. As 
of 2010, the medical device industry’s 
total global revenue reached $296.81 
billion and it is estimated that this market 
will grow by 6% to reach total revenue of 
$314.62 billion by 2011 as shown in Figure 
2 [5].  The red arrows in Figure 2 shows 
the growth trends that is predicted from 
2008 to 2011.  
The 2008 recession did have an 
impact on revenue for the medical device 
industry. The recession primarily 
impacted the industry’s revenue in the 
United States and the European Union. 
The EU region experienced a largest 
decline in revenue from 2008 to 2009 as 
shown in Figure 3 with red arrow. 
However, this reduction in revenue was 
offset by rise in demand from Asia Pacific countries as shown in Figure 3. Research conducted 
by Frost and Sullivan concluded that the industry recovered swiftly from the 2008 recession.  
Figure 2: Medical Device Market-Total Revenue: 2007 
to 2011 [5] 
Figure 3: Total Revenue Based on Major Markets:2007 
to 2011 [5] 
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In 2009, the United State alone spent $2.5 trillion dollars on healthcare; this amounted 
to 18% of its total GDP (U.S Healthcare spending).Today, 40% of the total global medical device 
industry revenue is from United States, which is by far the largest market. This is followed by 
the European Union and Japan [4].  
In 2007, there were as many as 5,300 medical device companies competing for revenue 
in the United States [19]. Interestingly, the medical device industry, with revenues approaching 
$300 billion per year, is primarily controlled by only 30 major companies, which comprise nearly 
80% global revenue (Figure 4).  The remaining 20% of the medical device market revenue is 
shared by multitude of medium and small organizations [19]. Seventy-three percent of medical 
device companies in the United States employed less than 20 people and as such are 
categorized as small businesses. 
 
Market research has categorized 
medical devices into twenty-one specific 
subcategories based on different medical 
field specialties. The Compound Annual 
Growth Rate (CAGR) versus current 
market size for each category is shown in 
Figure 5.  Ten of the largest segments 
include: Orthopedic, Cardiovascular, 
Vision Care, Wound Care, Hospital 
Figure 4: Medical Device Market: Top 30 Companies Ranked Based on Revenue [4] 
Figure 5: CAGR and Total Revenue Each Medical Device 
Category [5] 
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Supplies, Surgery, Audiology, Neurology/ Neurovascular, Radiotherapy and Mobility Aids.  This 
method of categorizing the medical device industry provides a means to view the big picture 
perspective of the industry because the definition for the medical device is so broad. Figure 5 
offers insight into both the annual growth and the size of medical device specialties; however, it 
does not identify the specific sources of growth within each medical device specialty. 
The overall outlook for the medical devices market is positive with an annual growth 
rate projected at 6%, which could further increase if the world economy recovers. Currently, 
the demand for medical devices will likely increase with the increasing demands for better care 
from East Pacific region and the increasing life span of Baby Boomers who will require ever 
more medical care as they age. However, if the world economy fails to recover leading, higher 
unemployment and or further austerity measure taken by nations could potentially impact the 
growth of the medical device industry. 
1.1.2 Medical Devices-In Vitro Diagnostic 
To obtain a clearer picture of the medical device industry, medical devices are 
categorized based on function, settings of use and purposes of use. Medical devices have four 
main functions: diagnosis, therapy, monitoring, and telemedicine. The diagnostic function is 
further broken down into in vitro and vivo diagnostic. The primary focus of this thesis is medical 
devices used for In-Vitro Diagnostics (IVD) for use in laboratory and Point of Care (POC) setting. 
In-Vitro is a Latin word which means in glass, and it refers to tests conducted outside of living 
organisms on specimens taken from the subjects [4].  The breakdown of IVD market based on 
revenue and function is shown in Figure 6.  
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IVD devices are typically complex systems that include reagents, consumables and 
analyzers. The integration of information technology with IVD devices has morphed these 
devices into intelligent systems. Just like cars today, which provide the driver with more than 
means of transportation, the IVD devices are capable of providing the users with functions 
beyond their intended primary use. Today IVD devices are multifaceted; they can generate 
billing information and automatically log patient test results into databases, give training to the 
users, perform automated quality control checks and serve as accessing terminals.  
1.1.2.1 In Vitro Diagnostic Market Overview 
 The IVD can be further refined into the following 
subcategories: Hematology, Tissue Diagnostics, Self-
Monitoring of Blood Glucose (SMBG), Hemostasis, 
Molecular diagnostics, point of care testing, Microbiology 
and Immunochemistry [4].  In 2009, companies producing 
IVD devices generated combined revenue of $39 billion 
dollars, which is expected to  reach $50 billion dollars by 
2014 [4].   As of 2009, 80% of IVD market was 
controlled by only 14 companies as can be seen in Figure 
7 [4].  Interestingly, this number is up from 2002 where 
the majority of the IVD market was controlled by only 6 major companies [20].  2 out of the 6 
companies that used to dominate the IVD market in 2002 no longer existed as of 2009 due to 
mergers and acquisitions. The 14 companies that make up the 2009 IVD market are as follows: 
Figure 6: IVD Total Revenue Break Down [4] 
Figure 7: Company Market Share as 
Function of % Revenue [4] 
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Roche Diagnostics, Siemens, Johnson & Johnson (J&J), Abbott Diagnostic, Beckman Coulter, 
Bayer Diabetes Care, bioMerieux, Sysmex, Alere, Becton Dickinson, Instrumentation Laboratory, 
Qiagen and Radiometer. Several of these companies such as Roche Diagnostic compete in all 
types of IVD, while others such as Radiometer specialize in one or two types of IVD area.  
It is important to note that not all parts of the IVD market will experience same level of 
growth in the future. The forecasted growth for different segments of IVD market is displayed 
in Table 1. 
 
For example it is expected that the Molecular Dx revenue will double from 2007 to 2014 
while Hematology revenue will only grow by 7% total for 7 years or by 1% per year. 
1.1.2.2 IVD Market Drivers Challenges and Trends  
Frost & Sullivan conducted a market research of IVD market in 2010. Frost & Sullivan 
reports the major drivers, challenges and trends for overall IVD Market; this is shown in the 
following Figure 8.  The overall message of this report suggests that the IVD market will remain 
competitive and that the competition will increase.  Relative to the device itself, the two most 
significant trends are automation and connectivity.  
Table 1: Predicted Revenue as Function of IVD Type [4] 
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Figure 8: Market Driver, Challenges and Trends [4] 
Opportunities for the use of medical devices within emerging markets are growing; but 
the demands in these regions of the world are not well-understood.  While the demand in 
emerging markets such as China and India is growing rapidly, a large segment of the population 
is still poor and live in rural areas. While major urban hospitals will acquire the latest and most 
advanced medical devices for their care centers, there are major potential markets in rural 
areas that have not yet been capitalized upon due to obstacles in affordability. Some 
organizations are beginning to recognize the potential of this segment of the market. For 
example, “In 2009, GE introduced a $1,000 electrocardiogram device and a $15,000 portable 
ultrasound machine that it had developed in rural India and in rural China, respectively. That 
new paradigm, dubbed "reverse innovation," has the promise to bring lifesaving technologies 
•The Rise of Global Aging Populations. (Example: The U.S Baby Boomer Reaching Retirement will require 
more care to stay health) 
•Increasing Global Incidence of Certain Diseases.  (Example: Diabetes) 
•Overall Increasing IVD Market Size. (There are exception for some segments of IVD market) 
•Shift in Focus from Disease Prevention and Health Promotion 
•Increase Demand for Devices with Connectivity Solutions, Remote Monitoring and Data Management. 
•Demand for Products and Services that Increase the Diagnostic Laboratory's Productivity. (Example: 
Improve throughput)  
•Unaddressed Testing Needs Create Opportunities for New Tests. 
•Adoption of Next Generation Sequencing and Other Novel Genomics Technologies. 
•Governments Healthcare Reform Increasing Investments in the IVD Market. 
•Strong Growth in Emerging Countries. (Example: China and India) 
Market Drivers 
•Increase Buying Power of End-User Pricing Pressures Continue to Restrain Overall Market 
•Adoption Restrained by Associated Switching Cost of New Analyzer and Methods 
•Global Economic Downturn caused End-Users to Delay Large Capital Purchases in 2009 
•Decline in Insured Population Drove Down Testing Revenues. 
Market Challenges 
•Importance of Customer Service. (Example: Brand recognition) 
•Continually Improve Analyzer to Meet Demand from End-Users (Example:  integrating connectivity in the 
devices) 
•Automation Across All Segments. (Example: Automated Sample Process) 
•IVD Organization Global Expansion (Example: Expanding to China) 
•Rising Number of 510k Approvals in the U.S.( Example: rise in competition) 
Trends 
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to developing countries and to establish lower price points for products in existing markets 
therefore presumably generating a healthy stream of sales in both markets.” [21].   
1.1.3 Regulation of Medical Device Development 
The FDA is one of the most important stakeholders for medical device companies given 
that it is currently the gatekeeper to the larger IVD market in United States.  Starting in 1976 
FDA became actively involved in regulating the medical device. Prior to 1976, medical devices 
were loosely regulated where, companies did not even have to follow any Good Manufacturing 
Practices (GMP), maintain records or report product requirements.  Most importantly, IVD 
manufacturers did not have to get FDA approval for their product[22]. In 1976, FDA passed an 
amendment to required medical device companies to register with FDA. Medical Devices were 
categorized into three classes. Class I medical devices consisted of devices such as tongue 
depressor. These devices are simple and not used for sustaining or supporting life and are 
subjected to least regulatory control known as “general controls”[22]. Class II medical devices 
are devices such as glucose meter, X-ray, MRI perform functions that require more regulatory 
oversight. These devices have the potential to harm individuals. The FDA has more stringent 
rules for approval of such medical devices.  These devices must meet both the “general 
controls” and “performance standards” to be qualified by FDA [23]. The Class III is the last class; 
this class includes devices such as pacemaker, artificial heart.  These are medical devices that 
support or sustain life or critical to preventing impairment to humans, thus they are subjected 
to the most stringent oversight by FDA [22]. Class III devices are required by the FDA to obtain a 
premarket approval prior to distribution.  
In 1990, the Safe Medical Devices Act (SMDA) was passed which gave the FDA the 
power to impose civil penalty and recall authority over medical device companies [23].  THE 
SMDA also gave FDA two tools, which are “post-market surveillance” and “device tracking”.  
Both of these tools are applied to class II and III devices and require medical device company to 
monitor their products performance after the product is sold to customers.  In, 1996 FDA came 
up with the Quality System Regulation (QSR) which adopted the ISO 9002 and required medical 
device companies to have processes for design, purchasing and servicing of medical devices 
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[22].  QSR also requires medical device organizations to trace user needs throughout the New 
Product Development Process NPDP to the final product (Figure 9).  The FDA does not require 
medical device company to follow any particulate NPDP as long as the process satisfies the FDA 
traceability requirement.   
However, in order to meet the QSR, medical device organizations are required to choose 
NPDPs that enable the organization to maintain full traceability. 
1.2 OBJECTIVES 
The IVD market segment is going through a tectonic change. Some segments of this 
market that are currently profitable will experience stagnation and while other segments will 
experience rapid growth and increased market size. IVD companies that specialize in specific 
IVD segment or segments which are experiencing stagnation must work hard to maintain 
product differentiation and innovation of new test menus to spur demand in order to survive. 
These companies must reduce manufacturing costs and invest in new tests for existing 
Figure 9: Application of Design Controls to Waterfall Design Process [13] 
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platforms. The main innovations in this field will be limited to the addition of new features to 
existing product architecture rather than developing new platforms.  The reason for this 
strategy is because this market will grow at slow pace and investing significant dollars to 
develop a new platform will be perceived as fruitless, because by the time the product is 
complete the demand will be furthered diminished by entrance of new competitors from Asia 
Pacific.  R&D failure is not an option because a failure may spell the end of era for such 
organizations.  As a result, some of these companies may choose to expand to other IVD 
segments that are experiencing growth. This requires such organizations to invest in the R&D 
groups that can act fast, which requires R&D group to acquire new competencies in order to 
enter new segments of the market. 
The current incumbents in the IVD segment experiencing growth will be under 
significant pressure to innovative. These organizations will face stiff competition due to market 
growth opportunities.  Growth in emerging markets such as China and India may require these 
organizations to develop new products that meet the specific market needs of these nations.   
One of the most vital qualities of successful organizations in today global economy is 
innovation. In a 2010 survey conducted by McKinney group, it was found that 84 percent of 
executives say innovation is extremely important to their companies’ growth strategy. In 
addition, all of companies surveyed expressed that they are actively seeking to grow in the 
coming years [24].  Today’s global economy requires organizations to have a product 
development process that can consistently produce successful products. Research and surveys 
conducted over several decades by PRTM, Booz-Allen-Hamilton, McKinsey & Company, Robert 
Cooper and others have shown that sixty percent or more of the total revenue of successful 
organizations comes from new products. A new product is defined as product that has not yet 
reached its halfway point of its Product Life-Cycle (PLC).  In order to maintain constant revenue 
from new products, organizations need to constantly develop new products that maintain the 
organization’s current market share and allow for growth into new markets. 
Given the importance of innovations to future of IVD companies, companies must 
benchmark their NPDP in order to identify the strengths and weaknesses of their NPDP.  Once 
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NPDP is benchmarked, a company must act swiftly to address the weakness of its NPDP. By 
adopting NPDP best practices, companies will be able to increase their chances of maintaining 
their competitive edge in this ever-changing and competitive environment. 
This benchmark will examine the NPDP of an IVD Company, to identify the weaknesses 
and strengths of its NPDP.  The benchmarking outcome also serves as an independent check to 
verify if the steps being taken to improve NPDP are valid and that the new NPDP is consistent 
with FDA application for design and control.  The particular company under examination is 
experiencing rapid growth both in its market shares and in organization size. The R&D group 
alone has gone from 60 to over 120 employees in less than 5 years. The top management of 
this organization have always acknowledged that the R&D department is the backbone to the 
company’s success, and consider the R&D group as the key to maintaining future growth. In 
2009, the R&D department underwent a major restructuring to address rapid R&D and market 
demand growth for new products. The process of restructuring included everything from a new 
workplace which promotes more employee interaction to a new management structure.  The 
strengths and weaknesses of previous NPDP are known to some degree due to a limited 2008 
study conducted by a consulting group. As a result, by benchmarking known data, one can 
verify if the PMG benchmarking method is valid for benchmarking this organization. The 
following two questions were proposed and addressed as part of this thesis. 
1. What are the gaps and strengths of this organization’s NPDP?  
2. Is the Performance Measure Group (PMG) method of benchmarking valid for this 
organization? 
1.2.1 Methodology 
The benchmarking of an organization’s PDP is not a trivial task; measuring the overall 
success of the product development effort has been challenging because there is no widely 
recognized standard used to measure NPDP effectiveness [9].  In the same vein, using a proven 
methodology to benchmark NPDP is very important. This thesis was completed in cooperation 
with PMG a division of PricewaterhouseCoopers (PwC) and a medium size IVD medical device 
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company.  PMG is a well-established organization that specializes in benchmarking.  PMG has 
over 30 years of experience in benchmarking as well as a database that consists of more than 
700 organizations.  
The benchmarking process conducted for this thesis was completed using two tools: 
questionnaires and interviews.  The questionnaires were developed by PMG. The 
questionnaires were segmented into five major sections and were given to various individuals 
who were involved in the projects.  After individuals completed the questionnaires, they were 
interviewed and asked to explain their answers to the questions.  The questionnaire results are 
summarized in a table format in the Results section and the interviews were used to explain the 
questionnaire results. 
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2 LITERATURE REVIEW 
2.1 INTRODUCTION 
The literature review consists of two topics: New Product development Process and 
Benchmarking. The New Product development Process literature review will focus primarily on 
two schools of NPDP philosophy: Phase-Gate and Spiral process. The Spiral and Phase-Gate 
processes are further explained individually in this Literature Review with examples of their 
application and use.  Bear in mind, NPDP is not limited to only these two methods and there are 
various approaches that fall in between these two styles of NPDP.  The benchmarking literature 
review examines various benchmarking methodologies. It also covers characteristic of good 
benchmarking questioner and the process that makes a benchmarking a successful. 
2.1.1 What Is New Product Development Process  
The NPDP is known by various names that are either too process-specific or too generic.  
Examples include such names as follow PDP, New Product Process (NPP), Gating System, 
Phased Review Process, Phase-Gate System, Product and Cycle-Time Excellence (PACE), Spiral 
Produce Development, Product Launch System and Stage-Gate System (Robert G 1994). The 
term NPDP is used throughout this thesis because it represents a solution-neutral PDP. The 
intent of this thesis is to portray a complete picture of NPDP and allow the IVD organization to 
choose a NPDP that best fits its culture, product lines, and organization complexity. 
 
Modified Versions 
Major NPDP Methodaligies 
Solution-Neutral 
NPDP 
Iterative  
Spiral XP 
Hybrid 
NexGen 
Stage© 
Phase-
Gate/Water
Fall 
PACE® 
Stage-
Gate® 
Ext.. 
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Just as there are many names for NPDP, there many definitions for NPDP. The NPDP 
definitions range from fairly simple to complex. Examples of various NPDP definitions by well-
known NPDP researchers are compiled below:   
“NPDP is a sequence of steps or activities which an enterprise employs to conceive, 
design, and commercialize a product” -[25] 
“NPDP is the “recipe” for producing a product” -[26] 
“New Product Process: a formal blueprint, roadmap, template or thought process for 
driving a new product project from the idea stage through to market launch and beyond” -[27] 
 
NPDP coordinates the cross-functional activities of various disciplines including 
engineering, marketing, manufacturing, quality assurance, service, purchasing and 
partners/contractors, that all work together to develop a product that delivers value to its 
customers [14]. The main intent of the NPDP is to drive ambiguity out of the product 
development process by providing a framework or template for the development of project 
plans, milestones, definition of tasks and defining the roles and responsibilities for each 
discipline with the overall goal to mitigate or eliminate budget overruns, delays, risk and quality 
problems. 
2.1.1.1 Origination of Today NPDP 
Organizations have been developing products since the Industrial Revolution [28]. 
However, the New Product Development Process  of  today stemmed from NASA’s early project 
management practices [29]. Prior to 1968, the NPDP was not well researched/standardized or 
even a well-known segment of R&D process [30].  While organizations did practice some form 
of phase or stage process to develop products, the processes were neither unified and defined 
nor [31]. NASA’s practices became the foundations for today’s NPDP such as Stage-Gate system 
[29].  Post World War II (WWII), the United States’ civilian and military industries experienced 
growth and prosperity which elevated the United States’ status among world leaders in the 
military industry.  In order to maintain its competitive status, the U.S created National 
Aeronautics and Space Administration (NASA) in 1958 with the mission to develop complex 
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products and conduct cutting edge research to maintain the United States’ competitive edge 
relative to the former Soviet Union  [32].  The National Aeronautics and Space Act of 1958 
created NASA, which gave NASA governance over 8,000 employees and a budget of $100 
million dollars [32].  In order to manage development of complex products, NASA  needed to 
develop a standardized process to manage all of its product development activities to make 
planning more realistic,  to test the validity of the planning, to "harden" concepts into 
development projects, to serve as a mode of continuous review, develop a standard process 
across the entire organization and to increase competitions among various R&D labs within 
NASA [31]. NASA officially introduced its NPDP in 1968 and it called the “Phased Review 
Process” (PRP)  [31].  NASA’s PRP was adopted by the U.S military and from there it diffused 
into the mainstream organizations [29]. 
2.1.1.2 Adoption of Standard NPDP by Main Stream Organizations  
As NASA officially announced its PRP in 1968, academic and consulting companies began 
research and investigation of the NPDP. Organizations were becoming aware that producing 
successful products was not a random act. Further, Globalization was already affecting the 
market environment as early as 1968 and American organizations began experiencing intense 
international competition [28].  Rapid technological changes required R&D departments to 
become more efficient and flexible in order to keep pace with rapid market changes [28].  
Finally, consumer expectations were changing in the early Nineteen Seventies; consumers 
started caring about nuances, ease of product use and product differentiation. This resulted in a 
fragmented and demanding market [28].  The changes in the market along with that desire for 
an NPDP that could give organizations a competitive edge launched an interest in NPDP. There 
were two fundamental questions raised at the time that researchers wanted to answers: 
1. Does investing more in R&D result in more profit? 
2. Does having NPDP give an organization a competitive edge?  
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2.1.1.2.1 Does Investing More in R&D Result in More Profit? 
In 2004, Booz, Allen and 
Hamilton (BAH), one of most well 
respected consulting firm in world and 
the pioneer of R&D best practices 
tracking, conducted one of the largest 
and most comprehensive studies to 
date to answer the question of 
whether spending more in R&D will result in more profit. 1000 publicly traded organizations 
from around the world participated in this study. The results from this study was published in 
2005 and concluded there is no statistical correlation (Figure 10) between R&D spending and 
sales growth [6]. 
“It’s absolutely a myth that money alone will solve vexing technical problems. Rather, 
reckless funding largesse is actually a barrier to transformative innovation as it turns scientists 
into constituents with an incentive to maintain the status quo. Reasonable constraints are a 
spur to progress. Entitlement programs for scientists and engineers are a drag.”-Dr. Allan O. 
Steinhardt 
While the conclusions showed that spending more did not result in more profit or 
revenue for an organization, the study also concluded that spending too little on R&D activities 
hurt organizations in the long term [6].  The BAH study fell short of prescribing a universal 
percentage of total sales organizations should spend on R&D to guarantee return on 
investment or to promote growth. The reason that there is no universal prescription for how 
much money organizations should invest in R&D is determining an ideal budget for R&D 
spending is a complex task. This task depends on many variables and decision points influenced 
by endogenous and exogenous forces (Figure 11) such as industry trends, portfolio 
management, market demand, government subsidies and other variable that are unique to an 
Figure 10: R&D Spending vs. Sales Growth. [6] 
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organization [6]. 
 
The overall summary of BHA research concludes that successful R&D spending has the 
right level of investment that is coupled with intelligent processes to select ideas and projects, 
efficient product development processes and a R&D group that provides interaction between 
functional groups such as  manufacturing and marketing in development process [6].  
2.1.1.2.2  Does Having NPDP Give an Organization a Competitive Edge?  
Finding the correlation between having a formal NPDP and competitive edge has been 
challenging. The main challenge has been the fact that implementation of NPDP is difficult and 
that it takes several years of using NPDP before the implementation can bear fruit [33] 
“In 1970s, it took Toyota 7 years to implement a simple product development process in 
place”- Paul O’Connor 1994 [34] 
Figure 11: Managements Decision Points [14] 
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NPDP adoptions, despite evidence that they can give organizations a competitive edge, 
have taken place at evolutionary pace rather than at a revolutionary pace because of the 
complexity associated with NPD [30].  
“A firm with static NPD processes, policies and methods will find themselves falling 
behind. However, not even the Best firms have radically changed the face of product 
development, or its outcomes.”- Abbie Griffin [30] 
There have been many benchmarking studies of R&D department conducted in the past 
40 years by various consulting firms. Most of these studies have concluded that having a formal 
product development process will lead to a higher new product success rate [12, 30, 35, 36].  
The latest PDMA handbook concluded that top performing organizations all had several 
common characteristics. One of these characteristics is that they all had developed a well-
defined product development process unique to their market and technologies which gave 
them a competitive edge[33].  
2.1.2 Phase-Gate/Waterfall NPDP 
2.1.2.1 Introduction 
BAH 1968 research found that organizations did practice a form of phase-gate NPDP 
prior to 1968 [36].  The NPDP practices prior to 1968 was mainly developed in house and was 
therefore not well-understood [36]. Today’s Phase-Gate or Waterfall process is based on 
research conducted from the 1970s to the 1990s. This was developed on the backbone of 
NASA’s NPDP the Phase Review Process [29].  The PRP was not a successful process for various 
reasons; it was slow, involved a great deal of built-in bureaucracy and did not involve groups 
outside of R&D [29, 35].  The Phase-Gate process has been heavily researched since PRP and 
has been the most widely adopted NPDP by U.S organizations [35, 37-39]. The Phase-Gate 
NPDP is known by various name such as Waterfall, Life-Cycle Process, Toll Gate, Check Point, 
Product Launch System, Stage-Gate System and others, but for the sake of simplicity and 
uniformity in this thesis, the name Phase-Gate will be used [16, 29, 40].  The classic model of 
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Phase-Gate has 6 phases (Figure 12); however there are various versions of this process that 
range from four to seven phases [15, 41]. 
 
As the name Phase-Gate suggests, this method breaks down the product development 
into discrete phases and at the end of each phase there is a gate that serves as a checkpoint to 
verify that goals for each phase have been met [35, 39, 42].  If goals for a phase are not met, 
the group will repeat the phase until the goals are met for that phase, as shown by iteration 
circle (Figure 13). As for Cross-Phase Iteration (CPI), as shown with blue arrow in Figure 13, 
while it is possible, CPI is expensive and counterintuitive to Phase-Gate Process [40].  
The intent of Phase-Review which occurs at each gate is to present the stakeholders 
with project status and to allow the group to decide whether to proceed to the next phase, 
stop, or repeat the phase [12].  The group which attends Phase Review is called the 
“gatekeepers” and  usually consists of a cross-functional team including marketing, finance, 
R&D, management executives, quality assurance (QA), and regulatory and manufacturing 
personnel [12, 33, 35].  
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Figure 12: Generic 6 Phase NPDP- The Non-Iterative Version 
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2.1.2.1.1 Advantages 
The advantages of Phase-Gate NPDP is having a clear framework that forces the PD 
group to approach the process in sequence with clear delivery at each gates [43].  If the Phase-
Gate process is followed and implemented as prescribed, product definition, requirements and 
user needs are defined early in the product development process [40].  Another advantage of 
the Phase-Gate process is that is allows for the discovery of errors early in the product 
development process when the cost of rework is low [40].  Another advantage of Phase-Gate 
NPDP is that it brings the transparency of the project development process to upper 
management and cross-functional groups, such as marketing, QA and manufacturing.  Cross-
Figure 13: Iterative Phase-Gate/Waterfall 
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functional group involvement in Phase-Review passes the responsibility of product success to 
these groups as well, thus demanding that these groups be proactive in the product 
development process [12].  For example, by involving the manufacturing group in Phase-
Reviews, the manufacturing personnel can confirm that the PD team has met the 
manufacturing needs.  The broadest advantage of the Phase-Gate process is the structure that 
it brings to the product development process. Finally, the Phase-Gate process reduces R&D 
spending by eliminate projects where the investment in project is low , very early in phase 
development [12].  As shown in Figure 14 the management has the option to stop a project at 
any Phase-reviews. 
 
2.1.2.1.2 Limitation and Disadvantages 
One of the most well-known limitations of classic Phase-Gate is its inflexibility.  The 
Phase-Gate process is sequential. Therefore, if a step within Phase is delayed, this would result 
in a delay of a Phase-Review which would ultimately delay the whole project [44].  Phase-Gate 
NPDP does not favor Cross-phase iteration because of the significant cost associated with 
repeating a phase and added time to the overall product development [44].  These 
characteristics make the Phase-Gate process unfavorable for use in cases when the user needs, 
market opportunity, and business case, are not well defined  [16, 40, 44]. The Phase-Gate does 
not handle change or feature creep, the process is not designed to handle scope creep that can 
occur late phase. 
Another disadvantage of the Phase-Gate process is the bureaucracy that it can 
introduce to NPDP. The intent of Phase-Review is to ensure that the goals for phase have been 
Figure 14: Phase-Gate Go or No-Go Decision Points [12] 
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met. However Phase-Review can turn into the micromanaging of the technical team by upper 
management as was the case for NASA during 1970s [31].  McGrath research concluded that 
the amount of contribution from upper management is reduced as the product advances from 
one phase to another (Figure 15) [12].  Having all stakeholders at all phase reviews is important, 
however it is most important to invite the right stakeholders to phase reviews in which they are 
in a position to bring valuable input [12].   
 
2.1.2.1.3 Modified Variations of Phase-Gate 
Due to Phase-Gate popularity in United States, 
many refined and specialized variations of the Phase-
Gate process have developed. One popular process is 
the V- model (Figure 16). This process turns the Phase-
Gate process into V shaped process. It takes out 
Validation and Verification Phase (V&V) and instead it 
uses V&V as link between phases.  This process breaks 
down the technical risks in order to increase traceability 
and quality control during the product development process.  
Figure 15: Management Contribution and Impact [12] 
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These variations of phase-gate are designed to enhance the generic Phase-Gate process 
and to address various shortcomings of the Phase-Gate process. At first glance, the major 
differences between these processes is the number of phases [14]. For example, Basic 
concurrent engineering by Don Clausing has 4 phases, Product and Cycle-time Excellence 
(PACE®) and Stage-Gate® Process - two of the well-known Phase-Gate Processes - have 5 phases 
and Elaboration on the cross-functional Product development process has 7 phases as shown in 
Figure 17.  The real difference between modified Phase-Gate processes is the description of 
each phase and gate and the emphasis on what best practices the organization should employ 
[14].  
 
The most important difference between the generic and modified processes is the 
implementation of parallel activities that can occur in these modified processes [25, 38, 42, 44-
Figure 17: Various Versions of Phase-Gate Processes [14] 
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46]. For example as shown in Figure 18, multiple subsystems design activates can occur in 
parallel. 
   
There are other added values that these modified Phase-Gate processes bring that go 
beyond boundaries of NPDP. The major added value relates primarily to portfolio management. 
There are other benefits, however covering all of these benefits is beyond the scope of this 
thesis.  These added values could provide wider differentiation among these processes if the 
organization decides to go with the Phase-Gate process. 
2.1.3 Iterative NPDP Process 
2.1.3.1 History: 
The Iterative NPDP Process has become synonymous with the Spiral NPDP Process and 
software development.  However the Iterative NPDP has a rich history that dates back several 
decades. 1930 Walter Shewhart developed “Plan-Do-Study-Act” (PDSA) cycle as a means to 
make continuous improvement to processes [47, 48]. PDSA became the backbone of the 
Iterative and Incremental Development process practiced during development of X-15 (1950s), 
Mercury and later adopted by IBM Federal System Division [48]. The software development 
community of 1970s and 1980s was frustrated with Phase-Gate product development [49].  The 
main source of frustration stemmed from the development of a detailed specification for a 
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product where user needs where not fully understood. These specifications proceeded with 
development which resulted in a product that didn’t meet the user need [49]. 
“The Waterfall Model is Wrong!” -Fredrick Brooks 1995 
“The waterfall model is dead, No it isn’t, but it should be”-Barry W. Boehm 1988 
In 1980s Barry Boehm developed the first formalized iterative product development 
process called Spiral Process to help streamline and manage risks associated with software 
development [47-49].  
2.1.3.1.1 Spiral Product Development Process 
Spiral product development process manages the risks associated with not fully knowing 
the user needs, market size and technologies capabilities, by providing a framework that allows 
for continuous iterative process until all risks have been resolved. The framework for the Spiral 
PDP, shown in Figure 19, starts with several iterative cycles in which the team goes through risk 
analysis, prototype 
development, requirement gathering, requirement validation development plan until all risks 
Figure 19: Spiral NPDP [7] 
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have been resolved before proceeding with development process which follows a waterfall 
process [7, 40, 49].  The initial cycles are meant to be rapid and short; the team develops 
prototypes that can be given to users to better understand workflow, intended use and such. 
2.1.3.1.2 Advantages 
The main advantage of the Spiral process is the flexibility that it offers to team.  The 
development team can start a project without having the full requirements. The development 
team is not slowed down by paperwork until all the gaps in requirements are identified and 
addressed. The development team can easily iterate between phases.  Risks are spread over 
multiple cycles and as a result risk is managed in a controlled environment [50]. The Spiral 
process promotes a flexible design in which dynamic environments can be advantageous to the 
organizations and would allow for implementation of change in later phases [40].   
2.1.3.1.3 Limitation and Disadvantages 
The Spiral process’ main disadvantage is its complexity, as a number of cycles within the 
Spiral process increase the complexity of managing product development increases.  The Spiral 
process puts greater pressure on managers to manage cross-functional activities and to keep 
the development team focused on the end goal [50]. With flexibility comes cost and longer 
development time. In cases when the budget and schedule are the drivers of the project, the 
Spiral process can be disadvantage [40]. Traceability can be lost over time if design decisions 
are not well documented in the early cycles.   
2.1.3.1.4 Hybrid NPDP Processes 
There are several hybrid processes such 
as Evolutionary Prototyping and Delivery, 
Extreme Programming (XP), Ad Hoc (example: 
Code-And-Fix), Design-To-Schedule or Budget, 
Scrum, Rapid Application Development (RAD), 
Figure 20: Design-To-Schedule or Budget [8] 
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Commercial Off-the Shelf (COTS) and others. These hybrids’ NPDP are specific to a driver of 
product development. For example Design-to-Schedule or Budget (Figure 20) is a Waterfall 
process that has been modified to accommodate product development which are under budget 
or time constraints. Application of these NPDP must be done under full evaluation of product 
development goals and organization strategy.  For example, Design to Schedule should not be 
applied to projects where the drivers are quality.  
A comprehensive evaluation of each of these NPDP would be out of scope of this thesis. 
Steve McConnell’s book Rapid Development: Taming Wild Software Schedules does a great job 
of explaining each of these processes in detail. McConnell compares ten NPDPs side by side 
using eleven criteria which capture the strengths and weaknesses of the NPDPs (Figure 21). In 
Figure 21 the strengths are noted as Excellent, and weaknesses are noted as Poor, and 
indifferences are noted as Fair[8]. 
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2.1.4 NPDP Conclusion 
“Customize the NPDP framework for each business unit. One process does not fit 
all.”([51]). 
Today, there are many NPDPs that an organization can adopt, each with its own 
individual weaknesses and strengths. The important conclusion is that there is no one NPDP 
that would fit all of the needs of an organization. Product development drivers can vary from 
product to product; therefore having a single NPDP is no longer viable.  The days to conform 
each product development effort to a single product development process are over. In today’s 
dynamic environment, NPDPs must match the risks and characteristic of each given product. A 
holistic approach to product development process is to accept the NPDP as a tool; each NPDP is 
designed for a specific job. A medical device is system of systems made of complex software, 
mechanical, electrical and chemical components. In some cases multiple NPDPs might be 
applicable to large project. For example, the software development of product can follow a 
spiral or XP product development process while the hardware can follow the Phase-Gate 
process.  Research has shown that many successful organizations have multiple processes for 
product development. 
2.1.5 What Is Benchmarking? 
2.1.5.1 Brief History 
In the 1980s, Xerox and Robert C. Camp helped establish benchmarking as an important 
tool for organizations to continuously improve their processes, practices and performance [52-
54].  It is important to note that Xerox and Camp introduced benchmarking to the mainstream; 
however other firms such as PRTM and Booz-Allen-Hamilton had developed benchmarking 
processes before this period [30].  In 1979, Xerox faced stiff competition from Japanese 
organizations who were able to manufacture products at lower costs with higher quality when 
compared to Xerox [52].  Xerox realized that as organization it needed to continuously improve 
the manufacturing process in order to remain competitive [54]. Xerox responded to these 
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threats by benchmarking its American operation versus its Japanese subsidiary FUJI XEROX [52].  
The benchmarking was intended to identify gaps in its manufacturing unit when compared to 
the parallel Japanese manufacturing unit and to learn from new practices that the Japanese 
employed to make their manufacturing more efficient  [52].  In 1989 Robert C Camp and Xerox 
published a book called Benchmarking: The Search for Industry Best Practices that Lead to 
Superior Performance which details Xerox’s experiences with benchmarking. Since 1989, 
American Express, IBM, Kodak, AT&T, Chevron, 3M and Xerox have employed benchmarking as 
important tool to improve their organizations’ performance [55-57].  
2.1.5.2 What Does Benchmarking Mean Today?  
“Benchmarking: to study (as a competitor's product or business practices) in order to 
improve the performance of one's own company”- Merriam-Webster 
Over the years, many scholars have devised unique ways of defining benchmarking; thus 
benchmarking has many definitions.  Table 2 lists some of the most widely accepted definitions 
of benchmarking as established by major scholars and firms. Having so many definitions for a 
single word is overwhelming; however, there is a common theme to all of these definitions. 
Benchmarking is a systematic process of measuring an organization’s process (es), practice (s) 
or product(s) by comparing and measuring them against external or internal standard(s). The 
purpose of determining the organization’s weaknesses and learning from BIC organizations on 
how to improve these weaknesses [52, 53, 57-63]. 
Table 2: Lists of Benchmarking Definitions [53, 58, 61] 
Authors Definitions 
Camp (1989) “The continuous process of measuring products, service and practices 
against the toughest competitors or those companies recognized as 
industry leaders” 
Geber (1990) “A process of finding the world-class examples of a product, service or 
operational system and then adjusting own product, services or 
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system to meet or beat those standards.”  
Alstete (2000) “An ongoing, systematic process for measuring and comparing the 
work processes of one organization to those of another by bringing an 
external focus to internal activities, functions or operation” 
Codling (1992) “An ongoing process of measuring and improving products, services 
and practices against the best.”  
Watson (1993) “The continuous input of new information to an organization”  
Cook (1995) “A kind of performance improvement process by identity, 
understanding and adopting outstanding practices from within the 
same organization or from other businesses.”  
APQC (1999) “The process of continuously comparing and measuring an 
organization against business leaders anywhere in the world to gain 
information that will help the organization take action to improve its 
performance” 
 
2.1.5.3 Types of Benchmarking 
Benchmarking has been utilized in many areas of industry and several types of 
benchmarking types have been developed over years. Not all of these benchmarking types have 
been well studied by major scholars. There are seven standard benchmarking types that have 
been studied and published by a number of scholars and firms.  The eight standard 
benchmarking types are known as process, performance, functional, strategic, internal, 
external, competitive and generic benchmarking [64].  Each type of benchmarking has unique 
applications. Process, functional, performance and strategic benchmarking process refer to 
what is being benchmarked while internal, external, competitive, and generic processes refer to 
who the benchmarking is being compared to [57].  
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 Process benchmarking is a process by which an organization seeks to better understand 
its critical process, weaknesses and strengths when compared to BIC organizations with 
similar processes [55].  Data for this type of benchmarking can come from any industry 
with a similar process. This benchmarking is not suitable for benchmarking of the whole 
organization because it is intended to focus on a single process at a time [57] such as 
billing, complaint, inventory, schedule management and other processes [52, 59, 64]. 
Short term gains are normally expected from implementation of recommendations 
resulting from this benchmarking   
  Performance benchmarking is a process that compares the performance of an 
organization’s product(s) and service(s) relative to its competitors [59]. This 
benchmarking is commonly conducted by organizations to establish their ranking within 
their industry [11]. 
 Strategic benchmarking is a process that compares an organization’s core competencies 
and capabilities, organizational structures and management practices to other 
organizations [63, 65].  It is used by top level management professionals to assist them 
with the development of the organization’s long-term plan.  Strategic benchmarking has 
an impact on the organization as a whole. 
 Internal benchmarking is a process in which the performance of a unit, division or 
subsidiary within an organization is compared and measured to other units, divisions or 
subsidiaries [59].  This benchmarking has two popular applications. The first application 
is to learn best practices from a unit, division or subsidiary within the organization and 
apply these best practices to the rest of the organization. The second application, 
popular with consulting firms, is to motivate, consolidate or terminate unproductive 
units within an organization.  
 Competitive benchmarking is process that measures an organization’s product designs, 
processes, and technological competencies relative to its direct competitors [11].  This 
benchmarking is limited to direct competitors. This benchmarking can be difficult and 
complex because obtaining information on direct competitors’ core competencies, 
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processes and strategies may not be possible [53].  When possible, gathering such 
information can require significant research. 
 Functional benchmarking is a process that compares and measures the functional or 
process performance in a specific area of an organization to measures of functional and 
process performance in the same areas as of BIC organizations [11]. The data for such 
benchmarking can come from various industries. This type of benchmarking is applicable 
to logistical distribution, purchasing functions and other similar activities [57]. Like 
process benchmarking, functional benchmarking is effective when used to benchmark a 
single functional area.   
 External benchmarking is a process that enables an organization to measure its 
performances in the areas of ideas, methods, products and services against those in 
organizations within the same industry [53]. External benchmarking is similar to 
competitive benchmarking with the exception that data for this benchmarking can come 
from organizations with in the same industry rather than direct competitors [66]. An 
example would be a car company benchmarking itself against computer and aircraft 
manufactures to learn how to improve its overall manufacturing process [53]. 
 Generic benchmarking is a process that measures and compares an organization’s 
processes and functional performance against BIC organizations across industries [53].  
Generic benchmarking is the same as functional benchmarking with exception that it 
benchmarks multiple processes simultaneously. 
2.1.5.4 Benchmarking Processes  
There are as many benchmarking processes as there are benchmarking definitions.  
Various scholars, firms and organizations have developed a total of over forty different 
benchmarking processes [53]. The major differences between these processes are the number 
of phases and number of steps involved.  A benchmarking process can have between four to six 
phases and multiple steps within each phase.  The standard benchmarking process has five 
phases and fourteen steps. The typical benchmarking process was built on Deming’s four 
stages: plan, do, check and act, which is shown in Figure 22 [53]. 
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The following is a typical benchmarking process developed by Bjørn Andersen and Per-
Gaute Pettersen and published in the book, The Benchmarking Handbook: Step-by-Step 
Instructions. 
1. Phase One is Planning: 
a. Determine what is to be benchmarked and the type of benchmarking 
required 
b. Define criteria of success 
c. Select benchmarking process 
d. Document the process 
e. Develop a performance measure 
2. Phase Two is Searching: 
a. Identify benchmarking partners 
3. Phase Three is Observing: 
a. Understand and documents partners’ process 
b. Understand and documents partners’ practices 
4. Phase Four is Analyze:  
a. Analyze the data collected 
b. Identify performance gaps 
Figure 22: Deming Four Stages Applied to Benchmarking [11] 
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c. Find root causes for the gaps 
5. Phase Five is Adapt 
a. Choose best practice applicable to the organizations 
b. Adopt to best practice to the organization 
c. Implement benchmarking recommendations 
2.1.5.5 What types of data collected for benchmarking? 
A typical benchmarking process consists of either quantitative or qualitative data.  
Benchmarking that combines quantitative and qualitative data is called a balanced scorecard. 
Quantitative data must be measured and collected in numerical form [53]. Examples of 
quantitative data are revenues, costs, outputs of assembly line, total numbers of products sold 
in a period of time and other measureable values.  This type of data is preferred by scholars, 
academics and organizations because quantitative data is easier to measure and identifying 
gaps is simpler [53]. This type of data is very useful in benchmarking the performances and 
features of similar product(s) or service(s). An organization can use quantitative data as part of 
internal benchmarking to identify performance gaps between two of its plants that produce 
same product. However, quantitative data does not always answer the question as to why 
there is gap [53].  
“Qualitative measures (input) indicated the performance of an organization in relation 
to its operation practices based on perceptual evaluation by assigning numerical value to each 
perceptual degree”- Metin Kozak [53] 
Qualitative data consists of information such as employees’ perceptions of 
management, management perception of core competency, customers’ needs, customer 
loyalty to the organization and other similar data.  Qualitative data has been very popular with 
marketing and customer driven measurement services for some time [57]. For example, 
qualitative data can be collected during competitive benchmarking to find out why customers 
prefer a particular brand of a given product.  Such data can give an organization an important 
insight into parameters that are not measureable using quantitative methods. 
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“You may have heard the world is made up of atoms and molecules, but it's really made 
up of stories. When you sit with an individual that's been here, you can give quantitative data a 
qualitative overlay.” -William Turner 
A balanced scorecard refers to the methodology of analyzing both quantitative and 
qualitative data to reveal existing gaps and reasons for these gaps [67].  For example, when 
General Motors benchmarked Toyota plants in the early 1980s, it discovered, using quantitative 
data, that Toyota had a superior process for assembling cars. Using qualitative data, the 
benchmarking discovered that the success of Toyota was primarily due to the empowerment of 
employees [67]. This methodology has been adopted by many organizations such as Toyota and 
Ritz-Carlton Hotels to improve their overall performance [67, 68].   
2.1.5.6 Summery 
It is very important to remember that benchmarking is a tool that helps organizations 
continuously learn from others and from themselves. In order for benchmarking to be effective, 
organizations need to spend time upfront determining what needs to be benchmarked and who 
they will compare themselves to in the benchmarking process. It is important to include 
organizations in benchmarking that bring value, such as BIC organizations, as they constantly 
evaluate and improve their processes. It must be remembered, however, that being the BIC 
organization today does not guarantee being the BIC organization tomorrow because BIC 
organizations must consistently remain up-to-date and efficient with all internal processes. 
Benchmarking can speed up an organization’s process of improvement as it produces new 
information about best methods. Ultimately, it is not the benchmarking process itself that 
improves the quality of an organization. Rather, it is the implementation of the resulting 
benchmarking recommendations that facilitate the improvements. 
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3 BENCHMARKING METHODOLOGY AND RESULTS 
3.1 INTRODUCTION 
In 1976, Pittiglio, Rabin, Todd & McGrath formed a consulting firm called PRTM.  In the 
Nineteen Eighties PRTM and Booz-Allen-Hamilton were among the first companies that had 
developed a process to measure the relationship between PDP and success of organization [30]. 
In early 1980’s PRTM developed a benchmarking process to benchmark product development 
and supply chain management [30].  PRTM benchmarking of R&D best practices showed that 
there are many deficiencies with current NPDPs used by organizations.  In 1988 PRTM 
introduced its own version of Stage Gate PDP called Product and Cycle-time Excellence 
(PACE)[12]. PACE is a framework that consists of both heuristic and other tools used to 
streamline innovative product development processes from conception to the end of product 
life.  
In 1992, as part of its NPDP benchmarking process enhancement, PRTM developed an 
index called the R&D Effectiveness Index (RDEI) [9].  The RDEI measure the effectiveness of R&D 
group by comparing the profit from new products to the investment in development of new 
products [9]. A simplified version of RDEI formula is shown below: 
     
                      (                ) 
    
 
In the above formula, the percentage of New Product Revenue  refers to revenue from 
products that have not yet reached half of their Product Life-Cycle (PLC) [9]. PLC is defined from 
time of product introduction to market to time the product is no longer produced [9]. The R&D  
percentage is current R&D budget on new product development only, divided by current 
revenue [9]. McGrath admits that obtaining an accurate R&D percentage is difficult because in 
many cases, organizations do not have granularity in their accounting breakdown. A reasonable 
approximation of R&D spending is satisfactory and will not have major impact on final result  
[38]. Net profit percentage is the actual or a representative average profit from new products 
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launched in the last five years which have not yet reached their PLC half-life [9]. PRTM research 
concluded that many companies faced difficulty accurately calculating their profit. As a result, 
an average was considered acceptable for their purposes [38]. A comprehensive RDEI is far 
more complicated than the simple formula shown previously. A complete RDEI calculation is 
more involved and would look similar to Figure 23. 
 
In 1998, PRTM spun off its benchmarking division and created a separate entity called 
the Performance Measurement Group (PMG) to provide its clients with unbiased benchmarks. 
While PRTM continues as consulting group, the PMG group focused on improving 
organizational benchmarking. PMG had four unique characteristic that made it ideal for this 
study. These characteristics are as follows: 
1. Large database of companies (over 700 companies surveyed across multiple industries) 
2. Industry specific benchmarking (PMG’ benchmarking questionnaire tailored for each 
industry. For Example: medical devices) 
3. Experience in Benchmarking (over 30 years of knowhow) 
Figure 23: A Comprehensive RDEI Calculation [9] 
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4. PRTM developed PACE® which has been adopted by many medical device companies 
5. Experience across the entire healthcare value chain (Figure 24)  
3.1.1 PMG Methodology 
3.1.2 Basic Principles behind PMG Methodology 
PMG benchmarking is built upon PRTM knowhow. The roots of PMG’s benchmarking 
questionnaire survey can be traced back to PACE and RDEI.  PMG benchmarking consists of five 
major sections: quantitative, qualitative, population comparison, PRTM insight and analysis and 
recommendation or balance scorecards (Figure 25).  These five components are used to 
diagnosis gaps and opportunities within organizational practices. It should be noted that in 
2011, PRTM and PMG were acquired by PricewaterhouseCoopers LLC. PRTM Insight is now 
known as PwC Insight. 
 
Figure 24: PMG Experienced Working Across the Healthcare Value Chain [3] 
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Figure 25: PMG Approach to Benchmarking 
3.1.2.1 Quantitative Section 
 The quantitative section of benchmarking, shown in green in Figure 25, is designed to 
measure multiple Key Performance Indicators (KPIs) that measure the value of R&D to the 
entire organization. The purpose of this section is to use various metrics such as organizations’ 
practices and performance and benchmark organization innovation strategies to peer 
organization. KPIs measure organizational behavior in five areas. These areas are innovations, 
productivity, response time, cost management and quality for products and NPDP. The 
quantitative section also measures the value (importance) of each of these behaviors to the 
organization. Using data collected in the quantitative section, the RDEI can be calculated.  Two 
examples for each of types of KPIs measured in the quantitative section are shown in Figure 26. 
A more comprehensive list is shown in Results section. 
Gaps and 
Opportunities 
= 
Balanced 
Scorecards 
Quantitative 
Benchmarks 
(1) 
Qualitative 
Benchmarks 
(2) 
Population 
Comparison 
(3) 
PRTM 
Insight 
(4) 
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Figure 26: Examples of KPIs Measured  [3] 
3.1.2.2  Qualitative Section 
The qualitative section measures specific Key Performance Levers (KPL) in twelve 
primary domains within an organization. These domains are: Innovation Excellence®, Product 
Lifecycle Management®, IT Enablement®, Software Practices®, Resource Management®, Design 
Excellence®, Technology Excellence®, Functional Excellence®, Development Chain Excellence®, 
Portfolio Excellence®, Product Excellence® and Project Excellence®. The purpose of this section is 
to understand the maturity of an organization’s innovation selection, NPD, and lifecycle 
management processes (Figure 27).  
•% Revenues from New Porducts 
•Number of New Technologies Developed in Past Year 
Innovation 
•Pipleline Throughput 
•Number of ECO Per Engineering 
Productivity 
•Schedule Integrity 
•Respond to Market Opportunity 
Response Time 
•Project Budgets 
•Product Reuse 
Cost 
•BOM Accuracy 
•Engineering Changes Post Launch 
Quality 
•What is The Value ($) of Innovation to the Organization? 
•What is The Impact of R&D Budget ($) On The Orgnaization?  
Value 
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Figure 27: The Qualitative Section Focuses Process Maturity  [3] 
3.1.2.3 Definitions: 
1. The Best-In-Class (BIC) represents the average data for the top 20% of organizations 
from the selected populations. In the case of this benchmarking, it represents the 
average of two organizations. On a normal distribution graph, the BIC represents the 
95th percentile of the distribution[69]. In case of this benchmarking, the data from the 
benchmarking were compared to 10 organizations. The BIC represents the average data 
for two organizations from selected data base.  
2. The Average represents the average data for 60% of population selected. In the case of 
this study, it represents the average data for six organizations. 
3. The Median represents the middle values [69].Ten organizations from PMG’s database 
were selected for this study, thus Median is average data from two organizations who 
data fell in middle of the database. If the data are normally distributed, the mean and 
the median will be close. If the data are not normally distributed, and then both the 
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mean and the median may give useful information. For example, for On-Time Delivery 
Performance, if the BIC is 95% and median value is considerably less than the average, 
then the data are skewed and more than half the companies have significantly lower 
performance than average [69]. 
4. The Worst-In-Class represents the average data for the bottom 20% organizations from 
the selected populations [69]. In the case of this benchmarking, it represents the 
average of two organizations. 
5. NR: Not Relevant 
6. ND: No Data or Insufficient Data 
7. TOP or Bottom refers to the average of the top or bottom 20% of respondents for that 
metric [69]. For example in some cases the data is not compared to other organization 
but to the data collected within organization the data was collected.  
8. Medical device organizations were selected for this study based on two factors. First 
criteria was based the product architecture, whether a product had integrated or 
modular architecture. The second criteria was based on similarity of the product, 
preferred organization would have been direct competitors or operate in the same 
industry with similar products. For more information see section 3.1.4. 
3.1.3 Use Context and Challenges 
3.1.3.1 What was Benchmarked 
3.1.3.1.1 Background of the Organization Benchmarked 
Until the year 2008, this organization had two R&D divisions.  The two divisions were 
known as the Division One and the Division Two. Each R&D division was dedicated to one 
product line. The two R&D divisions were approximately the same size and worked in complete 
isolation from one another. Each division had its own unique process and approach to NPDP 
and the two product lines were very different from each other. There were no overlaps in 
technologies or services that each product line provided.   
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As part of organizational restructuring in 2008, the company morphed the two R&D 
divisions into one. Since the restructuring took place recently, there is not much data about the 
current PDP.  Influences from the previous R&D divisions are still strong in the consolidated 
R&D department.  The organization is currently in the process of developing a new PDP; 
therefore it was concluded that a single benchmarking assessment would not be sufficient to 
determine the gaps in the current PDP. To compensate for the organizational restructuring, two 
benchmarking surveys were conducted in 2010. The two R&D divisions had started and finished 
a platform development project around the same time. This was the last platform development 
effort that these two divisions had undertaken as separate entities.  Each benchmarking result 
was then compared to a separate custom population of previously benchmarked companies by 
PMG/PRTM with similar products and functions. Due to the recent merging of the two 
departments, this benchmarking assessment could not fully assist the organization in 
identifying the best NPDP to address both product lines’ needs.  The organization structure is 
shown in Figure 28.  
 
Figure 28: Organization Structure 
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3.1.3.1.1.1 This Organization’s PDP Process 
In 1999, after a major restructuring of the R&D department, the organization switched 
its NPDP from phase-gate to spiral. The intent of adopting the spiral PDP was to allow the R&D 
department to respond faster to issues discovered during the development phases and not to 
get slowed down by gates.  There is one fundamental difference between the spiral PDP 
discussed in the literature review section and the spiral PDP that this organization adopted in 
1999. In traditional spiral PDP process (used to develop software), prototypes are built early in 
development process and are given to the user and iterations occur based on customer 
feedback. In the early phase of the spiral PDP, this organization customized the process by 
building breadboards and evaluating various functionalities and individual performances of 
critical subsystems.  The rationale for the variation of the spiral process was to validate that the 
concepts selected for the product met the organization’s goals for the project. This phase of the 
PDP is called the Feasibility phase. Once all the goals were met, the project moved into design 
control that consists of four phases that fall into of the design control category. The four phases 
are Prototype Design, Pre-production Design, Production Design and the Launch Phase.   After 
the Feasibility phase, the rest of the process was typical of a spiral PDP. A summary of high level 
tasks associated with this organization’s NPDP is shown below. 
1. Concept Phase 
a. Tasks 
i. Idea Generation 
ii. High Level Requirement Generation 
iii. Business Justification 
iv. Product Line Strategy Review 
v. Risk Analysis 
2. Feasibility Phase: 
a. Tasks  
i. Develop Product Architecture  
ii. Develop Specific Subsystem to Reduce Risk 
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iii. Perform Iterative Breadboard Testing to Validate Feasibility of the 
Concepts Selected 
iv. Refine Design of Various Subsystems 
3. Prototype Phase 
a. Tasks 
i. Preliminary Integration of Software, Electrical And Mechanical 
Components. 
ii. Limited Functionality Testing 
iii. Limited Analytical Development 
4. Pre-Production Phase 
a. Tasks 
i. Full Hardware And Software Integration 
ii. Proof Of Integration 
iii. Analytical Parameter Development 
iv. System Proof Of Performance 
5. Production Pilot Phase 
a. Tasks 
i. System Validation Testing 
ii. Marketing And Service Group Training 
iii. Beta Site Evolutions (Usability And Performance Evaluation By The 
User)  
iv. Seeking Regulatory Approval 510K 
v. Transfer Of Documents And Training Of Manufacturing Personal 
For Production 
6. Launch Phase 
a. Limited Distribution Phase 
i. Tasks 
1. Business Risk Review 
2. Marketing Literature Are Updated 
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3. Business Analysis Are Updated  
4. Process Are Audited 
b. Full Distribution 
i. Tasks 
1. Worldwide Product Launch 
3.1.4 Who was Benchmarked 
For the benchmarking study of the Division One, ten companies were selected from 
PMG benchmarking data base.  The following organizations were selected because they were 
direct competitors or had products with similar complexity: Abbot, Affymetrix, Alcon, Bayer 
Corporation, Boston Scientific, Hollister Incorporated, Hospira Inc., Johnson & Johnson, Smith & 
Nephew and Tyco Healthcare.  For the Division Two, ten companies were selected from PMG 
benchmarking database. The ten companies selected for the second benchmarking are: Bayer 
Corporation, Becton Dickinson Diagnostics, Bio-Rad, Hollister Incorporated, Medtronic, Ortho-
Clinical Diagnostics, Philips, Siemens AG, Smith & Nephew and Spectranetics.   
Throughout this section, the results are presented in table format. Each table compares 
the results from organization to Best, Average, Median and Worst in class.  The Best, Average, 
Median and Worst in class are relevant to the populations selected for the benchmarking study 
and it is not comparable to the whole medical device industry. As part of the survey, the data 
providers were interviewed to gain soft information, such as how strictly employees follow the 
NPDP, to explain the results. These interviews also helped to determine the relevance of survey 
results to the organization. 
3.1.4.1 Challenges 
There were several challenges to the benchmarking process. The first major challenge 
was getting data for two platform projects that had taken place over 10 years ago. Each project 
took over several years to complete. Acquiring and organizing data was very challenging. In 
some cases, finding accurate data was impossible. In such cases, a best estimated guess by 
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subject expert was sought.  An example of this case involved finding the number Engineering 
Order change (ECO) submitted to manufacturing six months after product was released. The 
company had changed from paper format to electronic format to track ECOs. The data that was 
needed for this benchmarking was in paper format and accessing and analyzing this data was 
beyond the scope of this thesis so the best estimate guess by subject matter expert was placed.  
Other challenges stemmed from the organization’s restructuring. As result of the restructuring 
of two R&D divisions, some positions where consolidated. Finding individuals who still possess 
the necessary knowledge became a major task in and of itself. Another major challenge was 
acquiring exact individual data regarding administrative and IT spending as both departments 
shared a single account. In addition, IT spending did not differentiate between NPDP and 
support for released products. According to McGrath, one of founders of PRTM and an avid 
researcher in the field of PDP, use of a single account for several purposes within a company is 
common practice in many organizations. To determine the company’s individual spending on IT 
and administration, the shared account was simply divided in half and reported.   
3.2 Method of Collecting Data for PMG Benchmarking 
For this benchmarking study, PMG created two separate online accounts for each R&D 
division. The benchmarking questionnaires were available electronically through these secure 
accounts. Data entry was also done using these secure accounts. After the questionnaires were 
completed and reported to PMG, PMG would lock down the editing features on accounts and 
would conducted data validation. The data validation process checks the quantitative data for 
inconsistencies. For example in cases where replies to several questions had to add up to 100% 
if the data did not add up to 100% the system would generate error and requested for 
clarification. Once the data validation is completed, the data is analyzed using PMG proprietary 
methodology. It is important note that the exact formulas and methodology used to calculate 
these results were not shared with this research 
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3.3  RESULTS 
This results chapter is divided into three sections. The section 3.3.1 is comprised of 
results from a public case study by PMG. The sole purpose of this section is to serve as a 
reference point for publication readers to get a sense of output result by PMG.  No actual work 
was done by the author of this thesis to produce these results. Due to confidentiality, the actual 
results for the benchmarking are not shared with the public. The organization benchmarked is a 
privately held corporation, who does not share any financial or technical information with 
public.  
In section 3.3.2 the benchmarking data is analyzed using Design Structure Matrix (DSM).  
In this section, a model of the organization NPDP is created and the interdependencies of tasks 
within the NPDP are examined. Section 3.3.3 reports the advantages and disadvantages of 
organization’s NPDP based on employees interviews. 
3.3.1  Result from PMG Case Study Company A 
The data presented in this section are not based on real organizations. This data is 
shown as an example of results presented to the benchmarked company. All of the results 
presented here are the copyright of PMG. The intent of this section is to present the reader 
with sample results presented to the client, since the actual results section of this thesis is 
confidential and not available to public. The client’s results are not publishable due to 
confidentiality. Instead, PMG provided us with sample results exhibited in their marketing 
brochure. Company A does NOT exist and results for company A are sample results used by 
PMG for marketing. 
3.3.1.1 Company A Background 
Company A is a medical device company that makes a handheld full body scanner and 
analyzer. Company A has become the market leader in field of imaging thanks to Phoenix 2000. 
Phoenix 2000 is the world’s first handheld full body scanner and analyzer which was released 5 
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years ago. After the release of the product, Company A experienced rush of demand. The 
company experienced rapid growth, and head counts 
went from 50 employees to 800 employees within 2 
years.  The company lunched 13 other products since the 
Phoenix 2000. At the moment, company A’s overall 
competitive strategy (Figure 29) is to continue being an 
innovative company followed with investments in 
understanding and improving customer intimacy. Finally, 
Company A is committed to reducing manufacturing 
costs. In the year 2000 and in the last year the company 
was listed on stock exchange. Since being listed on stock exchanges the company has been 
under pressure to continue its double digit growth. The management considered innovation as 
key competitive advantage. Thus, they hired PMG to benchmark their R&D process. After two 
months of work, the following results were delivered to the upper management of Company A. 
3.3.1.2 Results 
3.3.1.2.1 Quantitative Results 
Figure 30 lists the results 
for PDP maturity for the whole 
organization. Organization A has 
robust practices for all stages 
except for the portfolio platform stage where the process can be improved to be competitive 
with BIC organizations.  
The financial comparison results are shown in Figure 31.  The result shown in Figure 31 
indicates that Company A revenue growth (CAGR) is not on par with (other) BIC groups. 
Company A needs to improve its revenue growth to maintain its competitive market edge. As 
for reset of the financial indicators, the organization has average performance and there is 
Figure 29: Competitive Strategies [3] 
Figure 30: Organization A Product Development Practices  [3] 
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room for improvement. 
 
In Figure 32, the left graph shows the average breakdown of R&D spending for Average 
organizations. In total, these organizations spend nine percent of their budget on advanced 
technology, sixteen percent on product platform, twenty one percent on minor product 
modifications, twelve percent on platform for major markets and lastly thirty seven percent on 
platform for major existing markets.  Company A R&D breakdown is the graph shown on the 
right side of Figure 32.  The breakdown of R&D spending for company A is follow: advanced 
technology (17%), product platform (0%), minor product modification (10%), platform for major 
new markets (30%) and lastly platform for major existing markets (40%) and the rest of R&D 
budget is spent on non-product related actives. 
 
Figure 31: Financial Performance Comparison  [3] 
Figure 32: R&D Breakdown Spending for Average and 'A’ Organization [3] 
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In Figure 33, breaks down the total revenue for bottom, BIC (Top) and Company A.  This 
figure shows the percentage of total revenue those results from new product launches from the 
year 2002 to the year 2006. About 71% of Company A’s total revenue from product launch in 
the last two years is on par with BIC organizations. 
 
Product development time and the time it takes for major products to break even for 
company A are shown in Figure 34.  In the medical device industry, the average project takes 
about 30 weeks to break even. In Company A, the slowest project took 94 weeks and the time 
to break even was 70 weeks, while the fastest projects took 37 weeks to complete and 7 weeks 
to break even. This data indicates that the gap between the fastest and slowest project is 
around 120 weeks, which is large gap between the two extremes within this organization. 
 
Figure 33: Impact of New Product on Total Revenue [3] 
Figure 34: Product Development and Break-Even Time. [3] 
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Figure 35 lists the KPIs measured in the area of innovation and strategy, leverage and 
quality for organization A and compares the data with BIC and average organizations.  The data 
shown in Figure 35 exposes an area of improvement for Company A, as there is a large gap 
between Company A and BIC organizations. The data shows that organization A is not 
leveraging its platform product and is not spending a sufficient amount of its R&D budget on 
developing product platforms. However, Company A is performing equal to, or better than, 
average organizations. 
 
In Figure 36, the percentage of staff 
working on projects that generate revenue for 
Company A, and top and bottom organizations 
are shown.  Company A’s utilization of staff is 
13% below the top organization, but 16% higher 
than bottom organizations. 40% of R&D staff 
are working on projects that are not R&D related such as customer support, training and 
functional improvement.  
Figure 35: Innovation and Strategy, Leverage and Quality result [3] 
Figure 36: % PD Staff Activities Breakdown [3] 
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Figure 37 shows the number 
of management levels for Company 
A, top, bottom and average 
organizations. In the Top 20% of 
organizations, there are three levels 
of management while in Company A 
there are 5 levels of managements. 
Finally, in the bottom 20% 
organizations there are 6 levels of management.  As shown in Figure 37, there seems to be 
correlation between number of management levels and staff productivity.  
In Figure 37, the results for following KPIs speed, cost, quality and productivity as 
function of R&D spending are exhibited for Company A, top and bottom organizations.  
Company A did not provide data for cost section of the benchmarking; therefore this section is 
left blank. Company A’s results shows that when compared to top organizations, it performs 
poorly in response time, time to breakeven, schedule slip and number of products launch per 
equivalent R&D spending for major products.  
 
Figure 38: Speed, Cost Management, Quality and Productivity [3] 
Figure 37: Number of Management Levels in R&D [3] 
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In Figure 39, the results 
for hardware and software 
reuses for platform 
development are displayed. As 
shown in Figure 39, top 
organization platform products 
reuse up to 58% of hardware 
and software from previous 
generations, while Company A 
used only 20% of previous generation hardware and software.  The bottom organizations only 
used 10% of their hardware and software from previous generations. 
3.3.1.2.2 Qualitative Result   
This section of results covers qualitative results of the benchmarking. These results are 
more subjective and are dependent on the individuals who responded to interview questions. 
In order to make these results less biased, the questions were given to various individuals with 
an organization and results were then averaged. The individuals were able to answer the 
questions according to standards of ‘rare’, ‘occasional’, ‘frequently’ or ‘always’.   
Figure 40 compares Company A’s functional, project, product, portfolio and extended 
enterprise excellence to BIC and Average organizations. Overall, Company A performed well in 
all categories except for the areas of project performance management, portfolio governance, 
portfolio management process, portfolio performance management, collaborative projects, 
road mapping process and partner performance management. 
Figure 39: Hardware and Software Reuse for Platforms 
Development [3] 
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Figure 41 lists the results for Resource and Product Lifecycle managements, Innovation, 
and Technology excellence. The results in Figure 41, shows that Company A does not perform 
as well as BIC organization in innovation governance, innovation process, requirements 
management and product lifecycle performance management. As for the rest of KPIs shown in 
this table, Company A performs as well as BIC organizations. 
 
 The overall results summary for qualitative section is represented in Figure 42.  
These results show that various decision makers within Company A view the organization as 
doing poorly at portfolio, innovation, resource and technology management. 
Figure 40: Portfolio Maturity Practices and Governance and Process  [3] 
Figure 41: Resource, Innovation, Technology & Product Lifecycle Management  [3] 
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3.3.2 DSM Analysis of the NPDP  
3.3.2.1 What is DSM 
“The DSM method is an information exchange model that allows the representation of 
complex task (or team) relationships in order to determine a sensible sequence (or grouping) for 
the tasks (or teams) being modeled”- Ali A. Yassine 
DSM stands for Design Structure Matrix. DSM is a visual modeling tool that enables one 
to breakdown a complex system into subsystems while maintaining the relationships that exist 
among these subsystems [71]. DSM was developed in early 1980 to assist individuals to better 
understand the interdependency that exists between people and tasks, functions and 
components in complex systems[71]. DSM has been used to represent and/or analyze new 
product development process, project planning, product architecture and organizational design 
[71]. There are two main categories of the DSMs: Static and Time-based [71]. 
1. Static DSM is applicable to cases where components of a system exist at the 
same time. An example of such system is product architecture [71]. Static DSM is 
analyzed using clustering algorithms. 
2. Time-based DSM is applicable to cases where components of a system exist at 
various time and the sequence of the component indicates a flow through 
Figure 42: PD specific and Overall Qualitative Results  [3] 
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time[71]. An example of a Time-based system is NPDP [71]. Time-based DSM is 
analyzed using sequencing algorithms. 
A DSM model is a square matrix with identical column and row labels as shown in Figure 
43. Figure 43 shows the translation of a process with six tasks into a DSM model.  The X marked 
in column one of Figure 43 means that task 3 provides an input to task one. Columns in DSM 
matrix represent dependencies between subsystems of a system. Looking at row one of Figure 
43 the X mark represents the output of a subsystem. For example task one in row one of Figure 
43 provides output to task two and five. The blue filled squares in Figure 43 represent the 
mapping of subsystems to themselves. 
 
There are different methods of analyzing a DSM model; however the outcomes most of 
these analyses are the same. For analyzing the NPDP, partitioning is recommend method.  
Partitioning of a DSM model can assist with grouping of subsystems/tasks/actives and 
determining the interdependency and direction of flow. Figure 44 is DSM analysis of Time-
based process using the partitioning method.  
Figure 43: Example of a Process Mapped into a DSM model [1] 
Dep
end 
Provide 
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The green dots shown to the left of the black diagonal line in Figure 44 indicate that the 
downstream activities in a Time-based process depend on inputs from upstream activities. The 
red dots to the right of the black diagonal line in Figure 44 indicate that upstream activates 
depend on inputs from downstream activities. The grey box labeled series represents tasks that 
need to occur in series/sequential order. For example in Figure 44 task B must be completed 
before task C can start. The blue box labeled parallel represents task that can accomplished in 
parallel. For example tasks A and K can be performed in parallel and that there are no 
interdependencies between these two tasks. The brown boxes labeled coupled in Figure 44, 
represents tasks that are coupled together. Coupled activities require high coordination in 
order to minimize or eliminate unnecessary iterations.  
3.3.2.2 PSM32  
PSM32 is power software that 
enables one to develop DSM model. PSM32 
is developed by Donald V. Steward. The 
software is very simple to use and very 
effective in analyzing DSM model. The 
Figure 45 is an example of DSM model 
given in PSM32 tutorial.  Tasks are entered 
into rows. A zero is entered where ever 
Figure 44: An Example of DSM Analysis [2] 
Figure 45: Example of DSM by Donald V. Steward 
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there is dependency between a task listed in the row and task in column. Here is example from 
a software tutorial. 
For example, in Figure 45, the first row shows that item 1 depends upon items 2 and 4. 
The second row shows that item 2 depends on item 3. Row three shows that item 3 does not 
depend on items.  
3.3.2.3 DSM Model  
The data from the benchmarking in conjunction with interviews were used to build a 
Time-based DSM model using PSM32 software.  The NPDP process used by medical device 
organization was broken down into 80 critical tasks. Figure 46 shows the translation of the 
organization’s NPDP into DSM model. The result of partitioning of the DSM is shown in section 
3.3.2.4. As it can be seen in Figure 46, it is very hard to see if there is any interdependency or 
relationship between tasks. 
 Figure 46: DSM model of the organization NPDP 
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3.3.2.4 Result of the DSM 
The DSM model of the NPDP was partitioned and the result of this partitioning is shown 
in Figure 47.  There are five pink squares, numbered one through five in Figure 47.  Each square 
consist of a group of interdependent tasks.  Boxes numbers 1 through 3 shown in Figure 47, are 
relative small groups. The majority of the tasks shown in Figure 47 are Feed-Forward because 
they are located to the left of the black diagonal line.  There are several tasks that create a 
feedback loop within the pink squares. An example of tasks causing feedback loop is shown in 
Figure 47 with red arrow.   
 
Figure 47: Partitioned DSM 
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Box number one is shown in Figure 48, represents tasks in concept phase. The majority 
of tasks in this box is driven by marketing and top executives.  The major drivers in this phase 
are product line strategy and business risk analysis.  
 
Box number two shows the interdependent tasks within the Feasibility phase Figure 49. 
Concept testing is the driver of this phase. This finding is consistent with interviews conducted. 
What is interesting is that product requirement task is not part of this phase. This shows that 
the organization does not finalize product requirements until the end of feasibility phase. 
 
Box number three (Figure 50) is driven by initial electronic and mechanical design. These 
two principles are highly integrated due to the nature of the products this organization 
Figure 48: Concept Phase 
Figure 49: Feasibility Phase 
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produces. 
  
Box number four (Figure 51) is the largest box with highest number interdependent 
tasks.  This box represents the interdependent tasks with the prototype phase. The most 
interesting revelation in this box is the presence of several tasks from pre-production and 
production phase.   
 
Box number five (Figure 52) is the last grouping in partition DSM model.  This box 
consists mainly of tasks in production phase. There is a task from limited release phase that is 
highly dependent on tasks in productions phase of the developments.  This task is the start of 
limited release phase and cannot start until regulatory approval is obtained.  This 
Figure 50: Coupled Activities 
Figure 51: Prototype Phase 
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interdependency makes sense and suggests that goals for production must be met before 
limited release phase can start. 
 
3.3.3 Interviews: 
This section lists employee perceptions of advantages and disadvantages of the NPDP 
process. 
Advantages of current NPDP: 
1. Informal Approach to Feasibility and Prototype Phase: 
a. Engineers and scientists like the flexibility of the current process. The 
team is able to detect issues, identify the causes of issues and implement 
change(s) without having to gain approval from senior management.  It 
should be noted that this flexibility only applies to feasibility and 
prototype phase. In pre-production phase, this flexibility is restricted 
however to minor changes. Engineers still have freedom to make changes 
Figure 52: Pre-Manufacturing and Manufacturing Phase 
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without the involvement of upper management, but this flexibility is 
limited in design mode. 
2. Dedicated Core Team: 
a. The NPDP requires the formation of core team early in project life. The 
majority of the team members like this idea. 
3. Daily Stand Up Meeting: 
a. Daily stand up meetings are considered by many team members as an 
effective way of increasing the awareness of the project status and 
increasing communication between team members.  
4. Pre-Production Phase 
a. Manufacturing engineers like the fact that NPDP has Pre-production 
phase where manufacturing engineers get to work and learn from R&D 
engineers before full technology transfer to manufacturing. They prefer 
to start this involvement at earlier stage of NPDP.  
5. Flexibility to Modify the NPDP 
a. Project Managers like the fact that they are able to customize the NPDP 
based on their project complexity. 
6. Very Effective for Development of Major and Minor Products 
a. Groups found the NPDP process very effective for the development of 
major and minor products as well as the development of product that 
have defined product requirement. 
b. Very effective in developing of products do not involve technology 
development. 
7. R&D Involvement with product support. 
a. R&D is high involved with issues product support. This allows the R&D 
engineers to learn from the field and integrated what they learn into the 
new products..  
Disadvantages of the NPDP: 
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1. Not having formal NPDP 
a. Many engineers’ roles and responsibilities are not well defined for 
members of the NPDP team. The main source of confusion comes from 
the fact that each product manager can modify the NPDP process. NPDP 
terminologies have different meanings to different people due many 
years of customization of the original NPDP. New employees are not 
trained with the knowledge of the official NPDP process; thus they learn 
the NPDP through working on projects.  
2. The NPDP is Schedule -Driven: 
a. Many engineers found the process ineffective in developing new 
technology mainly because the NPDP is schedule-driven.  The 
development team is not given enough time to understand the new 
technology. 
3. Requirements are Not Fully Defined 
a. The current process does not demand requirement finalization until the 
end of the Feasibility phase. The benchmarking result showed that less 
than ten percent of product requirements change from beginning stage 
of NPDP to the final stage of the NPDP. Many engineers expressed that 
two to three critical requirements impacting product architecture are not 
finalized until the middle of prototype phase.  Many found this to be 
distracting and a source of delay in the project. 
4. System Integration is Delayed 
a. System integration is completed relatively late for new products and 
usually does not allow enough time for engineers to fully understand the 
impact of subsystems interactions with each other. Many engineers want 
to have more time to understand system interaction using empirical data 
rather than using theoretical calculation. 
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4 CONCLUSIONS AND RECOMMENDATIONS 
4.1 PERSONAL INSIGHT 
4.1.1 INTRODUCTION 
The purpose of this section is to share my personal challenges in conducting this 
benchmarking study in order to inform those who intend to embark on the challenge of 
conducting their own benchmarking studies.  The benchmarking process is a labor-intensive 
process. On average, for a midsize organization, it takes PMG two months to conduct a full R&D 
benchmarking. In order to conduct such a benchmarking, the PMG would send two of its 
employees, one full-time and one part-time to the organization. A member of the organization 
would assist the PMG employees for the duration of the benchmarking. For this thesis, two 
separate benchmarking studies were conducted for the two divisions of the organization. 
Originally, it was estimated that it would take four months to complete both benchmarking 
studies. However, it took six months to complete the studies for both divisions. It should be 
noted that PMG provided one individual part-time to assist with data processing. On average, 
the standard benchmarking by PMG includes sixty-four hours of interviews with various 
member of the organization. However, I wanted the interviews to be my own work without 
being influenced by PMG. Therefore, It should be noted that the information gathered through 
interviews was not communicated to PMG.  
4.1.2 CHALLENGES 
 “The benchmarking of R&D department is difficult because there is no standard process 
to R&D development that everyone follows”- Daniel Whitney 
While there are some commonalties among various NPDPs, most organizations 
customized these NPDPs for their own uses. The literature research for this thesis revealed that 
organizations follow many different NPDPs. My first challenge with conducting this 
benchmarking study was to convert the specific organization’s NPDP to the standard PGM’s 
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NPDP (PACE®). The benchmarking questionnaire was designed based on PRTM’s PACE® NPDP.  
The organization that was benchmarked followed a parallel Spiral NPDP. The organization’s 
parallel Spiral NPDP was converted to a sequential Phase-Gate before any questions could be 
accurately answered. The task of converting the organization’s NPDP from Spiral process to 
Phase-Gate process took one month because data was pulled from another benchmarking 
study conducted by the organization in 2008.  It had taken the previous benchmarking team of 
two full-time staff members three months to create this list.  This task was only possible 
because the organization kept track of time spent by project members on various activates 
within projects. Had this organization not kept a record of time spent on various projects, the 
accurate conversion of the organization’s NPDP to a standard NPDP would not have been 
possible.  This is a major challenge facing anyone who plans to benchmarked R&D processes. 
4.1.3 LESSONS LEARNED FROM BENCHMARKING 
Quantitative results do not always tell the whole story.  
The interviews that occurred as part of the benchmarking are as critical as the 
quantitative data collected for the benchmarking. This benchmarking was more than just 
handing out questionnaires to members of the organization and collecting responses. The first 
step of the process was to partition the questions into groups and distribute the questions to 
the right people. In cases in which it was not clear who could provide the most relevant 
answers, questions were distributed to multiple people. The questions were sent to many 
employees of various ranks.  This benchmarking was not a high priority for all employees, so 
constantly reminding individuals to fill out the questionnaires was essential. The most effective 
way of getting responses was to email the questionnaires to the individuals in advance and 
then setting up a meeting in three weeks time to review the completed questionnaires with 
them.  This was effective because it motivated the individual employees to look over the 
questionnaires and to be prepared for the meeting. During these one-on-one meetings, the 
individuals were asked to elaborate on their written responses to the questions the 
questionnaire. This was intended to extract soft information to better understand the context 
and the endogenous and exogenous forces that influenced result. Often, quantitative 
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benchmarking questions were followed by interviews of a qualitative nature to get a fuller 
picture. For example, one of the quantitative questions in the benchmarking study asked the 
following question: 
1. What percent of high level requirements changed during the NPDP?  
The answer to this question was ten percent. 
 The ten percent change in requirements is on par with BIC and did not flag any issues 
with the organization’s NPDP.  However during the interviews, it was discovered that a change 
to one requirement had added one year to project. This important information would have 
been missed if the final benchmarking conclusion had been based solely on quantitative results 
and data. 
“Empathic listening is listening with intent to understand the other person's frame of 
reference and feelings. You must listen with your ears, your eyes and your heart.” Stephen R. 
Covey 
It is vital to understand the interviewee reference points and how these reference 
points influence his or her responses. It is also important to expect that some interviewees will 
become passionate in their responses during these interviews because they are talking about 
something they care about, so listening empathetically helps facilitate the acquisition of 
qualitative data.  If the interviewee does not feel comfortable during the interview, he or she 
will not share their insights that are important to the benchmarking processes. 
  It is also important to know the interviewees’ frames of reference during qualitative 
questioning because this impacts the results of the benchmarking. This is especially important 
when accurate quantitative data is not available. The following is an example of such situation. 
Accurate data about the BOM (Bill of Material) was not available because the projects 
benchmarked for this thesis were over ten years old.  In order to answer the questions in 
regards to BOM, questions were asked of manufacturing and R&D engineers.  The R&D 
engineers’ responses differed greatly from the one from manufacturing engineers. After 
interviewing each team, it was discovered that manufacturing and R&D engineers had different 
understandings of BOM accuracy because they viewed this question from different frames of 
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reference. The R&D engineers’ understandings of BOM were limited and did not include all 
processes.  In this organization, manufacturing engineers’ understandings of BOM accuracy 
were very broad when compared to R&D engineers.  When the manufacturing engineers’ 
responses were reported to R&D engineers, the R&D rejected manufacturing claim. The same 
happened the R&D response was reported to manufacturing engineers. This finding was very 
important, because a decision had to be made to determine whose response should be 
submitted to the benchmarking.  Using a comprehensive understanding of each team’s frame 
of reference, an intelligent decision was made to incorporate the manufacturing engineers’ 
responses in the benchmarking. 
“For me context is the key - from that comes the understanding of everything”.-Kenneth 
Noland 
“In common use almost every word has many shades of meaning, and therefore needs to 
be interpreted by the context.”-Alfred Marshall 
Context plays a major role in understanding and explaining interviewee responses for 
the benchmarking results.  Without knowing the full context, one may compare apples and 
oranges.  An example of this happened when PMG compiled the benchmarking data without 
knowing the organization’s full history. This was done on purpose.  For the first data 
compilation, PMG was not provided with interview and organization insight.  The PMG team 
came to conclusion that one division spent excessive time developing new technology when 
compared to BIC and the second division benchmarked.  The real reason one division spent 
excessive time on technology development was the effect of an exogenous force and was not 
related to R&D’s NPDP. 
You think you are done, but you are not! Benchmarking is an iterative process! 
A successful benchmarking conclusion is based on a constant feedback loop between 
the members of the benchmarked organization and the organization that is conducting the 
benchmarking.  This constant feedback loop allows for the development of a complete story of 
the organization R&D’s NPDP.  Every time the benchmarking results as a whole are presented 
to the organization, more questions are raised, more soft information is extracted and a fuller 
picture of the organization begins to materialize. The more the employees of an organization 
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are involved in the benchmarking process, the higher the likelihood that the benchmarking 
recommendations will be implemented. For example, consistent involvement of manufacturing 
engineers in the benchmarking process motivated them to implement a new methodology of 
tracking BOM inaccuracies.  
Timing is everything! 
Nothing comes for free! 
Timing of benchmarking is a key.  Benchmarking should be done when the organization 
has the capacity to implement the recommendations from the benchmarking study. Without 
the intention to commit to implementing the recommendations from benchmarking, 
conducting benchmarking does not bring full value to the organization.  Benchmarking should 
not be done when the organization is about to embark on major a project or when the 
organization is in the middle of firefighting. The implementing of recommendations from a 
benchmarking study requires time, employee training and an expanded budget.  Any 
organizations planning to conduct benchmarking need consider time, budget and training 
needed to implement the resulting recommendations.  Some of key finding from this 
benchmarking were not implemented because the benchmarking conclusion came after the 
yearly budgets had been decided and because the organization at this moment did not have 
bandwidth to implement all the recommendations. 
4.2 ADVANTAGES AND DISADVANTAGES OF PMG BENCHMARKING 
4.2.1 Advantages 
PMG’s advantage is first and foremost getting unbiased overview of organization 
performance by a third party.  Whether the results of the benchmarking are positive or 
negative, the organization usually gives more weight to results from an independent source. By 
examining the whole organization the PMG is able to determine where communication 
between R&D and other departments such as marketing, manufacturing, service, and others, 
needs improvement. 
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“PDP differences are poorly understood and not yet fully acknowledged in existing 
literature and practice. As a result, companies have difficulty designing or selecting PDPs” 
Eppinger [16]. 
PMG and PRTM have a long history and knowledge in NPDP thus having them analyze 
NPDP and then having PMG helping the organization develop a personalized NPDP is 
invaluable. No two organizations are the same thus their NPDP should not be the same either. 
PMG with help of PRTM would help an organization through the NPDP selection and 
personalization and implementation process. 
4.2.2 Limitation 
Benchmarking old projects is very difficult, especially when the organization does not 
keep good records or if many members of the organizations have left. The benchmarking is 
designed to take the current pulse of organization, not what it was in the past.  
The benchmarking is designed for large organizations that work on 3 or more projects at 
the same time.  The benchmarking is not designed to benchmark only one or two projects.  The 
PMG benchmarking is based on Phase-Gate NPDP, so when benchmarking an organization that 
is not practicing Phase-Gate NPDP, it has to be converted to Phase-Gate. This process takes 
time and important information can be lost as NPDP is translated from one process to Phase-
Gate. 
The PMG benchmarking does include a regulatory section that covers the organization’s 
approach to FDA, EU and Japan regulations; however this section is weak and can be improved.  
In 2010, 32 Medical devices were recalled and 89 warning letters were sent out to medical 
device organizations for not complying with 577 GSR subsystem regulations. PMG 
benchmarking has the potential to expand their regulatory section and put more emphasis on 
how NPDPs can improve to meet regulatory demands. 
The mere existence of a formal product development process had absolutely no effect 
on performance. According to the benchmarking study, there was no correlation at all between 
merely having a formal process and performance results. The message is clear: those 
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companies who mistakenly believe they can "go through the motions" and reengineer their 
new product processes usually amount to documenting what they're already doing and they 
are in for a big disappointment.[27]. 
The presence of PMG members for benchmarking process is not necessary merely 
because of the benchmarking by itself. The rationale for their presence is the existence of 
instances where there were discrepancy between what was written and what was actually 
done. This is not common case limited to the organization benchmarked.  This is a common 
practice among large and small organizations [16]. 
4.3 CONCLUSION OF ORGANIZATION BENCHMARKING AND RECOMMENDATION  
The benchmarking results shows that many of the steps the organization took in 2008 
and 2009 to improve its processes were on par with benchmarking findings.  The organization 
spent less time on upfront activities which ended up delaying product launch and increased 
product development cost.  The organization sponsored a team of employees to go back to 
school to learn the latest methods of developing system architecture, requirement and systems 
approach to product development and implement these processes in the organization.  The 
benchmarking also found the organization’s need to separate technology from project 
development. The organization came to the same conclusion in 2009 and had begun the 
process of forming a technology development team.  Improving technology transfer from R&D 
to manufacturing was another area where benchmarking found that the organization could be 
improved by using information technology.  The organization had begun a process of 
developing a software platform to help facilitate the transfer of technologies from R&D to 
manufacturing. 
The benchmarking also found that current NPDP was not adequate and required 
improvements.  This finding was also confirmed with DSM analysis as well as interviews. The 
DSM shows that there are many interdependencies among tasks especially in prototype phase. 
For example, it was discovered that there was no common language for current NPDP used at 
the organization. Different individuals had different definitions for the various steps in the 
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NPDP.  This is something the organization also agreed that needed to improve.  To improve the 
NPDP the organization hired a director, who has experience working with PRTM implementing 
PACE® at large two major medical device companies.  As a group, it was concluded that this 
moment is not correct for the organization to implement a new NPDP. The rationale is as 
follows: implementing a new organizational NPDP requires the organization to focus on 
learning and implementing the NPDP. Based on average estimate from PRTM it would take 6 
months to implement a new NPDP.  It was decided that implement a new NPDP should be done 
at beginning of product developing cycle rather than in middle of product development cycle.  
The second reason for not implementing a new NPDP at the moment was to give time to all 
managers to get involve with process. This meant to introduce manager to various NPDP and 
getting them involve in selecting NPDP process.  This is right decision by the organization.  It 
takes time and effort to change a major process such as NPDP. It took Toyota 7 years to 
implement their NPDP, because they make their NPDP part of their DNA and culture [34]. 
As part of the benchmarking, many interviews were conducted with managers. 
Managers for most part favor a flexible NPDP because they felt that Phase-Gate would slow 
their projects down. However the benchmarking results identified this as a symptom of the fact 
that the organization does not spend enough time conducting up front activities and developing 
new technology as part of projects. As result of these two facts, it made sense for project 
manager to favor a flexible approach to product development. However with the changes the 
organization is implementing it is recommended that the organization follow a Phase-Gate 
process for device development.  The Phase-Gate process is more controlled. It reduces risks 
and it is more compliant with FDA GSR.  It is also recommend that the organization not to have 
one NPDP for the whole organization. 
“The best do not succeed by using just one NPD practice more extensively or better, but 
by using a number of them more effectively simultaneously” –Griffin [30] 
It is recommended to the organization develop three NPDPs: one for platform 
development, one for major product development and one for minor product development.  It 
is recommended all three NPDP have common language. Also the organization should repeat 
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the DSM analysis to confirm that the new process does a better job of managing tasks 
interdependencies within NPDP.    
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